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EPIGRAPH
Statistics is the grammar of science.
— K. Pearson
...the null hypothesis is never proved or established, but is possibly disproved, in
the course of experimentation. Every experiment may be said to exist only to give
the facts a chance of disproving the null hypothesis.
— R.A. Fisher
No problem can be solved from the same level of consciousness that created it.
— A. Einstein
The whole is greater than the sum of its parts.
— Aristotle
v
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Over the past decade, there has been steady increase of studies leveraging
genomic and related molecular profiling technologies to identify drug targets and
characterize drug effects for particular diseases. This is particularly true for cancer,
in which researchers can potentially identify genetic and other factors in tumors
to indicate appropriate treatments. Many relevant studies have leveraged high
throughput drug screen (HTS) strategies using, e.g., cancer cell lines that have
been profiled at the genetic and other levels. These strategies allow researchers to
assess the effects of many different drugs and compounds on cell lines exhibiting
wide variation in their genomic profiles, so that associations can be identified that
xxii
relate elements of those profiles with drug response. Unfortunately, given the
manner in which HTS studies are pursued and the amount of data they generate,
problems such as false positives or a loss of statistical power must be addressed.
These problems fall into three general categories: (i) the reliability of the screening
data and the procedures used to generate the data; (ii) the statistical analysis
methods used to identify associations between drug responses and other factors
collected on the cells used in the screening; and (iii) the differences between the
cell lines used in terms of their genetic architectures. I have taken a data-driven
approach to address each of these concerns.
First, I assessed the reliability and reproducibility of HTS data leveraging
two different collaborations. One set of analyses involved melanoma cancer cell
lines subjected to two independent laboratory drug screens. I ultimately assessed
the proportion of variation that could be explained by laboratory and technical
effects associated with the design of the experiments and found that when sources of
variation are quantified and controlled for, signals beyond “noise” can be detected
that reflect true drug response. A second set of analyses involved HTS to identify
drugs that influence lifespan in Caenorhabditis elegans. As with the study of the
melanoma cell lines, I examined the variability in the screening outcome data that
could be attributed to plate and plate-specific effects.
Second, I considered different ways of statistically analyzing dose-response
data arising from HTS experiments. I ultimately evaluated the performance of
nonlinear mixed effects (NLME) models relative to traditional models based on
an analysis of IC50 values derived from individual cell line drug response pro-
files. Through simulation studies as well as applications to actual data, I found
that testing for differences in dose-response curves using the NLME models has
greater statistical power to detect gene associations with drug responses than tests
involving traditional IC50-based values.
Third, I assessed differences in genetic co-expression among cell lines used
in drug screening studies. Such differences can dramatically affect identification
of gene/drug relationships. I find evidence for differences in the way genes are
related to each other between cell lines used in screening experiments and show
xxiii
how this “re-wiring” of genes can affect interpretation of resulting drug screen data
and identification of drug targets. Since more and more emphasis will be placed
on choosing the right treatment for an individual based on his or her genetic and
related profile in the future — as this is the goal of “personalized,” “individualized”
and “precision” medicine — I believe my analyses and approaches will motivate
future studies and lead to more reliable drug screening strategies and results.
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Chapter 1
Preface
1.1 Background
There is tremendous interest in using genomic and related molecular profil-
ing technologies with cell lines and other cellular systems to identify drug targets
and to characterize drug effects in pharmaceutical studies [Lamb et al., 2006]. This
is because genes, proteins, metabolites, and other molecular entities can be evalu-
ated as drug targets using a number of strategies involving cell lines [Krogan et al.,
2015]. In addition, the impact of specific drugs on those molecular entities can be
studied in a high throughput fashion using state-of-the-field infrastructure, making
it possible to efficiently screen thousands of experimental compounds and drugs.
Such studies can provide insights into the molecular mechanisms associated with
disease; the molecular and physiologic processes that are modulated via pharma-
cologic manipulation; and the factors that may mitigate response to a drug and
ultimately shed light on how the research community might specifically target or
“personalize” medicines [Barretina et al., 2012] [Yang et al., 2013]. But, there are
a number of complications associated with conducting and interpreting the results
of cell line-based drug targeting and screening studies. Though numerous, these
problems are generally associated with sources of variation and heterogeneity, and
fall into three broad categories: (i) the reliability and reproducibility of the data
generated by screening studies given the large number of potential sources of both
technical and biological variation inherent to their execution; (ii) the manner in
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2which claims about relationships among targets, drugs and modifying factors are
drawn via statistical methods, especially in light of the substantial heterogeneity
exhibited by individual cell lines at the genetic and molecular physiologic levels;
and (iii) whether or not the molecular systems to be interrogated exhibit variation
across cell lines so extreme that the study of any particular set of cell lines pre-
cludes easy generalization. The following expands on these issues as well as the
need for strategies that might be used to assess and overcome them.
1.2 Exposing and Accommodating Issues with
Heterogeneity in Drug Screens
As noted, drug screening studies require a great sensitivity to the inherent
heterogeneity across cell lines used and the different sources of technical variation
that complicate inferences from data analyses of those cell lines and their drug
responses. The specific sources of heterogeneity and how they complicate relevant
data analyses have been discussed in the literature to some degree, which we review
in the following.
1.2.1 Reproducibility
The reliability and reproducibility of cell line-based drug target identifica-
tion and screening initiatives have become a significant contemporary concern [The
CCLE and The GDSC Consortiums, 2015] [Haibe-Kains et al., 2013] [Safikhani
et al., 2016a]. The massive amount of data generated in drug screening experi-
ments raises questions about not only the reliability of the data, but also the rate
of potential false positive results if important variation sources are not accounted
for. For example, there is a need to quantify and control for purely experimental
sources of variation (e.g., different plating schemes, assays done in different labo-
ratories, different drug dosages, etc.). To address this, I studied various sources
of technical and biological variability in high throughput drug screen (HTS) data
generated by Sanford Burnham Prebys Medical Discovery Institute (SBP) and
3Translational Genomics Research Institute (TGen) as part of a project sponsored
by the Stand-Up-To-Cancer (SU2C) Melanoma Dream Team [Ding et al., 2017]. I
also assessed variation sources in publicly available databases, such as the Cancer
Cell Line Encyclopedia (CCLE) [Barretina et al., 2012] and Genomics of Drug
Sensitivity in Cancer (GDSC) [Yang et al., 2013]. Lastly, I considered experimen-
tal sources of variation (e.g., plate position, drug dosage, drug class, etc.) in an
independent organism-specific large-scale studies. In this study, I assessed varia-
tion sources in a HTS screen of drugs meant to modulate Caenorhabditis elegans
life-span [Ye et al., 2014].
1.2.2 Association Analysis Involving Dose-Response Data
Current strategies for identifying factors that influence drug response us-
ing cell lines rely on analytical approaches that may not be optimal for detecting,
e.g., gene/drug relationships. Previous attempts in community-driven drug discov-
ery challenges have demonstrated the utility of HTS studies but raised questions
about the approaches to analyzing the generated data [Bansal et al., 2014]. Typi-
cal analysis methods rely heavily on extracting single parameters meant to capture
dose-response relationships, like the IC50 value, that may generate issues for asso-
ciating those parameters with covariates and variation in drug response patterns.
Comparing existing methodologies with novel methodologies could shed light on
how to reliably and powerfully identify factors influencing drug response. I applied
both traditional and novel approaches, such as nonlinear mixed effects (NLME)
models, for relating covariates to drug response in an effort to identify factors that
mitigate drug response using the aforementioned SU2C, CCLE and GDSC data
sets. Based on the SU2C cell lines, I also performed simulation studies to investi-
gate the utility of NLME models relative to traditional analysis models, in terms
of their level-accuracy (sensitivity) and power (specificity) to detect the modifying
influence of factors on drug response. NLME model-based methods advantageously
balance the use of individual curves with group averaging, but are also more com-
putationally demanding than traditional analysis models. These simulations show
that NLME models accommodate statistical noise and are more powerful than
4the standard models that only exploit, e.g., IC50 values obtained from individual
dose-response curves.
1.2.3 Network Rewiring and Target Identification and Mod-
ulation
The manner in which genes, proteins and metabolites interact and function
as a whole in normal as opposed to disease states is likely to be very different
for obvious reasons. However, many drug target identification and target modu-
lation studies focus on the behavior of a drug or modifiable target in wild-type,
normal, or available and conveniently obtained cell lines. If differences of gene in-
teractions between normal and disease states are pronounced, then generalization
of drug activity assessed in normal cells to cells representing the disease state is
compromised. I explored differences among cell lines in terms of connections and
correlations among genes to characterize how much “re-wiring” among transcrip-
tional networks might exist between cell lines in normal and diseased states.
In my analysis, I incorporated both “supervised” and “unsupervised” meth-
ods of machine learning to identify evidence of rewiring. “Supervised” approaches
such as Evaluation of Dependency DifferentialitY (EDDY) [Jung and Kim, 2014];
Gene Set Enrichment Analysis (GSEA) [Subramanian et al., 2005] [Mootha et al.,
2003]; and Gene Set Co-expression Analysis (GSCA) [Choi and Kendziorski, 2009]
are limited to the settings in which the grouping of the cell lines is set in advance
and hence requires prior knowledge of, e.g., disease and normal conditions. Ulti-
mately, “supervised” methods require that each sample be identified as represent-
ing a disease or normal state. GSEA further assumes that each set of potentially
differentially expressed genes is independent and the probability of observing a
set of genes differentially expressed between conditions is equal. Similarly, GSCA
depends on identifying differences in the correlations between genes in previously
determined disease and normal states. Finally, although EDDY does aim to iden-
tify differential networks among groups of cell lines by incorporating probability
distributions defining dependency networks across many genes, it still requires the
prior specification of disease and normal conditions. “Unsupervised” methods do
5not require, e.g., disease and normal states to be specified in advance but generate
results that might be difficult to interpret or reconcile with the results of other
“unsupervised” methods. This is because they must search for groups in a data
set in addition to characterizing the differences between those groups. In addition,
although there are plenty of unsupervised methods used almost routinely in many
data analysis setting, most, if not all, of these methods only rely on exploring
differences in the means or mean vectors of the factors (e.g., gene expression val-
ues, protein abundances, etc.) among groups. Moreover, they do not consider the
correlations, connections or relationships — i.e., the “wiring” — of those factors
by exploring differences in, e.g., covariance matrices that reflect the connections
among the factors between identified groups. We assess evidence for network re-
wiring using both “supervised” approaches as well as “unsupervised” methods in
drug screen data and consider the implications such rewiring might have for making
claims about cell line responses to drugs.
1.3 Detailed Descriptions of the Data Sets Used
The data sets briefly mentioned in the previous section contain many nu-
ances that were important in my analyses. I was able to collaborate with inves-
tigators from various institutions to obtain complex proprietary data sets as well
as leverage public databases and resources that are also quite complex. In fact,
these complexities motivated many aspects of the quality control (QC) analyses I
pursued. The data sets I used to conduct my analyses are described in some detail
below.
1. SU2C data: The SU2C Melanoma Dream Team high throughput drug
screen data [Ding et al., 2017] was generated at the SBP in La Jolla, California
and TGen in Phoenix, Arizona. This data includes information about the experi-
mental factors and technical constructs used in executing the screens (e.g., plate,
laboratory, drug, dosage, etc.), which allows for the quantification and accommo-
dation of sources of variation in drug response attributable to these factors in the
6HTS experiments. In addition to this information, I obtained information about
different sources of biological variation that could impact the drug responses in the
screen. This included: Reverse Phase Protein Array (RPPA) protein abundance,
microarray whole genome gene expression, and melanoma-related cell line muta-
tional status information for each cell line used in the screens. The SU2C cell line
data was also used to define parameters for simulating HTS. We used these sim-
ulations to assess different methods for identifying drug x gene interactions (e.g.,
by defining drug sensitivity and resistance with NLME models and subsequently
associating response with mutation status, gene expression and protein abundance
information). Lastly, this data set was also used to assess evidence of network
rewiring.
2. CCLE and GDSC data: The CCLE [Barretina et al., 2012] and GDSC
[Yang et al., 2013] data sets are publicly available HTS dose-response curve data
sets that I used to perform an assessment of the sources of variation influencing
drug response. The CCLE and GDSC data analyses I performed are complemen-
tary to my analysis of the SU2C data [Ding et al., 2017]. Since the CCLE and
GDSC HTS do not use the same drug concentration ranges, I assessed sources of
variation in the context of previously determined and publicly available IC50 values
for each cell line and drug studied. I was able to obtain dose concentrations and
cell viability for each dose and drug administered in the CCLE data, but only had
access to the IC50 values for the GDSC data set. Additionally, plate information
was not available for these studies and could not be included in my comparative
analyses.
3. Caenorhabditis elegans life span data from Michael Petrascheck: This
data set was used to assess technical and experimental variation sources (e.g.,
plate position, drug dosage, drug class, etc.) contributing to 1280 drugs screened
for their ability to modulate C. elegans life span. I assessed the variability of the
screening data in the context of plate effects (including specific row and column of
plates), date, and the laboratory performing the HTS experiments.
74. The Cancer Genome Atlas (TCGA) [Cancer Genome Atlas Network,
2015]: This is a very large, scientific community organized data set with thousands
of patient tumors all having some kind of genome profiling done on them, such as
gene expression pattern characterization. I used the gene expression data to find
evidence of network rewiring in melanoma patients using both “supervised” and
“unsupervised” data analysis methods that consider (i) differences across groups of
tumors that are reflected in mean gene expression differences, and (ii) differences in
their correlations as reflected in covariance matrices. I obtained Melanoma TCGA
patient RNA-sequencing samples from the TCGA BROAD GDAC Firehose.
1.4 Synopsis and Discussion
Each of the analyses I pursued was designed to address a specific ques-
tion related to cell line-based drug assessment studies, but could be extended in
a number of ways. For example, as there are a number of published methodolo-
gies designed to relate particular pharmacologic manipulations and drug screens
to factors measured on cell lines and the cell lines’ responsiveness [Costello et al.,
2014], a comparison of those methodolgies would be ideal. My approach was to
(i) address issues plaguing HTS and drug target identification studies that have
received attention in literature and (ii) expose areas of additional immediate and
future research. This is highly appropriate for three reasons: (i) as genomic and
related profiling technologies become more efficient and cost-effective, they will be
used to identify potential drug targets and assess drug response in unprecedented
ways; (ii) the use of standard cell lines, such as available immortalized cell lines,
will likely be replaced with more sophisticated cellular constructs, such as fresh
cells, induced pluripotent stem cells, and organoids with similar problems as those
in traditional cell lines; and (iii) it is becoming increasingly clear that many fac-
tors mitigate drug response clinically as it is well-known that most commonly used
drugs only help a fraction of users. Identifying those factors in cellular models
could motivate the development of assays, companion diagnostic, and prognostic
8markers that could ultimately lead to “personalized medicines” [Johnson and Gal-
lagher, 2010] [Lupski et al., 2010] [Bainbridge et al., 2011]. These three reasons for
pursuing my studies also support the importance of anticipating future analytical
needs for HTS studies, since they will undoubtedly involve the combination of (i)
better and cheaper data generation technologies; (ii) a desire to understand drug
activity as a function of the potentially unique and nuanced profiles of individu-
als and their cells; and (iii) more biologically relevant and sophisticated cellular
systems. Thus, I believe our analyses and approaches will motivate future studies
and lead to more reliable drug screening strategies and results.
Chapter 2
Analysis of Variability in High
Throughput Screening Data:
Applications to Melanoma Cell
Lines and Drug Responses
2.1 Abstract
High-throughput screening (HTS) strategies and protocols have undergone
significant development in the last decade. It is now possible to screen hundreds
of thousands of compounds, each exploring multiple biological phenotypes and pa-
rameters, against various cell lines or model systems in a single setting. However,
given the vast amount of data such studies generate, the fact that they use multi-
ple reagents, and are often technician-intensive, questions have been raised about
the variability, reliability and reproducibility of HTS results. Assessments of the
impact of the multiple factors in HTS studies could arguably lead to more com-
pelling insights into the robustness of the results of a particular screen, as well as
the overall quality of the study. We leveraged classical, yet highly flexible, analysis
of variance (ANOVA)-based linear models to explore how different factors con-
tribute to the variation observed in a screening study of four different melanoma
9
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cell lines and 120 drugs over nine dosages studied in two independent academic
laboratories. We find that factors such as plate effects, appropriate dosing ranges,
and to a lesser extent, the laboratory performing the screen, are significant predic-
tors of variation in drug responses across the cell lines. Further, we show that when
sources of variation are quantified and controlled for, they contextualize claims of
inconsistencies and reveal the overall quality of the HTS studies performed at each
participating laboratory. In the context of the broader screening study, we show
that our analysis can also elucidate the robust effects of drugs, even those within
specific cell lines.
2.2 Introduction
High-throughput screening (HTS) strategies allow researchers to assess the
effects of thousands of compounds on drug responses in one large experimental set-
ting. Over the past decade, applications of HTS for drug discovery and drug effect
characterization studies have steadily increased, ranging from studies focusing on
the assessment of multiple phenotypic endpoints in high-content screening [Taylor,
2010], the evaluation of drugs on traits such as lifespan through the sophisticated
use of model species such as Caenorhabditis elegans [Ye et al., 2014], as well as
drug response pattern identification using massive amounts of genomic informa-
tion made available for crowd-sourcing efforts and community driven challenges
[Eduati et al., 2015]. HTS studies have also been pursued to advance personal-
ized medicine, especially in oncology settings, since tumor-derived cell lines can
be used in the screening studies to identify compounds that are active against
them or some subset of them. For example, large HTS databases — such as the
NCI-60 [Shoemaker, 2006], the Cancer Cell Line Encyclopedia [Barretina et al.,
2012] (CCLE) and the Genomics of Drug Sensitivity in Cancer [Yang et al., 2013]
(GDSC) have been made available to researchers for the express purpose of un-
covering drugs that exhibit unique effects against tumor-generated cell lines with
specific genomic profiles. In addition, very recent work involving the Connectivity
Map [Lamb et al., 2006] has exploited genetic network and pathway reconstruction
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methods to identify sets of genes that mediate specific drug responses in subsets of
cancers. In this light, the Cancer Cell Map Initiative [Krogan et al., 2015] (CCMI)
and related initiatives have not only drastically reduced drug discovery costs, but
have also guided efforts to identify genomically-informed, patient-specific cancer
treatment strategies. Unfortunately, as timely and as sophisticated as these ef-
forts have been, very recent studies comparing the quality of different HTS studies
meant to advance insights into personalized cancer care have raised questions and
concerns about their reliability and reproducibility as well as the interpretation
of the data they generated [Haibe-Kains et al., 2013] [The CCLE and The GDSC
Consortiums, 2015].
Assessing the reliability of HTS studies is not trivial given the number of
compounds typically considered, the number of reagents used, the way in which
constructs such as plating schemes and distributed robotic handlers are set up, the
manner in which dose response curves are constructed, and the fact that differ-
ent labs likely follow slightly, if not overtly, different protocols; i.e., the sources of
HTS cells, tissues or organisms, cell culture and assay conditions, reagents, con-
sumables and instrumentation are not standardized within the community. This
is particularly true for, e.g., tumor-derived cell line-based screening studies where
the nature of the source cell lines, their procurement and sustenance as well as the
responses measured on them may vary widely between different laboratories. In
addition, although diverse in execution, many cancer-oriented HTS studies focus
on cell counts upon stimulation with a drug that reflect that drug’s ability to kill
cells derived from a specific cell lines across differing drug concentrations. These
concentrations often range from inducing no response (i.e., no cells are killed) to
a very strong response (e.g., all the cells are killed). The dose ranges necessary
to achieve variation in the number of cells killed and establish a dose response
curve are very hard to anticipate often leading to different labs using different
concentrations and numbers of concentrations.
After having established the drug concentrations or doses to be used and
applying them to cells derived from a single cancer cell line, sigmoidal curves are
often fit to the cell counts associated with each drug dose to generate drug-specific
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dose response curves (DRCs). This is repeated for each cell line. The half minimal
inhibitory concentration (IC50) is then extracted from these curves [Shoemaker,
2006] [Barretina et al., 2012]. These IC50 values, which are often couple with
related response measures such as the area under each dose response curve (AUC),
are then used to determine the sensitivity or resistance of each cell line to the
different drugs. Recently, the IC50 and AUC results from two large cancer cell
line HTS studies, the Cancer Cell Line Encyclopedia (CCLE) and the Genomics
of Drug Sensitivity in Cancer (GDSC) studies, were used to assess the variability
of HTS assays pursued in this manner [Barretina et al., 2012] [The CCLE and The
GDSC Consortiums, 2015] [Yang et al., 2013]. The results of an assessment of the
comparability and reproducibility of CCLE and GDSC data sets by two different
research teams yielded opposing interpretations, which underscores the complexity
of HTS studies and their interpreration [Haibe-Kains et al., 2013] [The CCLE and
The GDSC Consortiums, 2015] [Safikhani et al., 2016b]. A third research team
recently reevaluated the CCLE and GDSC data and came to yet a different a
conclusion [Haverty et al., 2016].
In order to assess the reliability of HTS data, we conducted a study of intra-
and inter-site experimental variability across melanoma cell lines treated with 120
different drugs that are either in use in clinical trials or have been FDA-approved
for use in treating cancers. Our study was motivated by not only the controversies
surrounding the reliability of the CCLE and GDSC data sets, but also by our
engagement in a large clinical trial exploring the utility of personalized treatment
for late-stage BRAF wild-type melanoma [LoRusso et al., 2015]. We first measured
variability across replicated dose and drug applications to 29 melanoma cell lines
pursued within a single institution, the Sanford Burnham Prebys (SBP) Medical
Discovery Institute in La Jolla, California. The SBP studies were pursued using
two independent HTS formats and screens: a nine-concentration and a three-
concentration dose-response screens. Using the same 120 drugs and four of the 29
cell lines, we performed an independent nine-concentration dose response screen
at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. To
enable analysis of inter-site experimental variability, two copies of the master drug
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plates were generated at SBP. One was then ultimately used onsite at SBP and
the other was provided to TGen for their respective screens. Furthermore, the two
sites used the same final dosing concentrations and the same cell lines. All other
aspects of the screen were independent, resulting in variation in the environments in
the which the screens were pursued, personnel, compound freeze/thaw cycles, cell
passages, culture conditions, plating density, actual plates and other consumables,
and instrumentation.
To analyze the data produced from the two nine-concentration HTS stud-
ies, and to assess the variability of the results, we used flexible linear models and
analysis of variance (ANOVA) techniques. These traditional techniques allowed us
to examine how variation in drug responses (i.e., variation in the fraction of cells
killed for a particular cell line, drug and dose) is impacted by different factors, such
as the laboratory, the drug used, the plate on which specific assays were conducted.
We also considered interaction terms in the relevant (e.g., dose x drug interactions).
We chose not to generate dose-response curves and extract IC50 values for use in
our analyses, since our interests were in quantifying as many sources of variation
as possible and not condensing or obscuring any of them in dose-response relation-
ships reflected in single derived value. Thus, we modeled the dosage effects of each
drug as a separate independent or explanatory variable for drug response varia-
tion. It is well-known that models that are “saturated” in that they exhaustively
model the effects of independent variables and their interactions are inherently
linear. This fact is exploited in many contexts, most notably econometrics, to help
draw causal inferences between independent and dependent variables [Angrist and
Pischke, 2009]. Although we did not consider all possible interaction terms in
our models, we did consider most of them. Ultimately, our linear modeling and
ANOVA analyses allowed us to make comprehensive claims about that effects of
particular drugs and dosages on specific cell lines while accounting for factors built
into the design of the HTS, such a plate effects, that could induce variation in
drug responses. Thus, we believe our analyses can help identify signals of truly
statistically-significant drug effects over-and-above the “noise” created by various
factors, including individual laboratories and/or the individual plates upon which
14
cells were placed for drug effect characterization. We firmly believe that more so-
phisticated analytical methods, careful analyses, and interpretations of drug effect
claims in HTS experiments are necessary and will likely lead to the identification
and characterization of correctable sources of variation that may obscure HTS
results and shed light on claims about their lack of reproducibility.
2.3 Results
2.3.1 Variation of Cell Viability Data Across Dose and
Drug Replicates
Table 2.1 provides a brief summary of the data sets we considered in
our analyses. As an initial assessment of the consistency of drug-by-dose effects
across the 29 cell lines in common between the SBP nine-concentration and three-
concentration HTS studies (Figure 2.1), which comprise all HTS data obtained
at matching doses within the SBP HTS data, we considered the use of simple
correlation analyses. We found that the data cell viability data are not normally
distributed (Shapiro-Wilks test p-value < 2.2e-16 for drug responses for each drug)
and that the non-parametric Spearman correlation coefficient, rather than the stan-
dard Pearson correlation coefficient would be more appropriate for use in assessing
the consistency between the two data sets. We computed pairwise Spearman cor-
relations for the replicates at 0.1, 1.0, and 10.0 µM concentrations across each
drug and cell line (Figure 2.2A, Figure 2.5). Additionally, we calculated the cor-
relation coefficients using all available concentrations. As expected, the pairwise
correlations at the three concentration points suggested that a subset of the cell
lines showed greater evidence for reproducibility. These cell lines were identified
as those most likely to be sensitive to the drugs. This makes sense since the cell
lines exhibiting no response (i.e., does response curve) contributed only noise to
the correlations. In addition, within each dose, the distribution of the correlation
coefficients for each drug was skewed left (Figure 2.2B), with a long tail towards
negative correlations. This was the same when considering all dosages together,
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Table 2.1: Key: CLs = Cell Lines; MCLs = Melanoma Cell Lines; OCLs = Other
Cell Lines; CCLs = Melanoma cell lines in common with the SBP nine-point data
set; Common drugs = drugs in common with the SBP nine-point data set; SBPMDI
= Sanford Burnham Prebys Medical Discovery Institute; TGen = Translational
Genomics Research Institute; CCLE = Cancer Cell Line Encyclopedia; GDSC =
Genomics of Drug Sensitivity in Cancer
Data Set Doses (um) MCLs OCLs # Drugs CCLs Common Drugs
SBPMDI
1 dose
10 49 0 747 37 89
SBPMDI
3 dose
.1, 1, 10 30 0 120 29 120
SBPMDI
9 dose
.02, .04, .1, .2,
.4, 1, 2, 4, 10
40 0 120 40 120
TGen
9 doses
.02, .04, .1, .2,
.4, 1, 2, 4, 10
4 0 120 4 120
CCLE
8 doses
.0025, .008, .025, .08,
.25, .8, 2.53, 8
59 888 24 4 9
GDSC
8 doses
varied 45 1209 139 4 6
although there was an observed improvement in the correlation coefficient, which
may reflect a larger sample size (Figure 2.2C). This highlights the advantage of
considering the overall pattern of consistency for drug sensitivity profiles, as op-
posed to considering each dose individually. Thus, studies exploring the influence
of different factors on HTS results should pursue analyses reflecting variation in
the entire experiment, instead of just focusing on each individual drug, cell line or
dose in isolation.
2.3.2 Variation Between Two Laboratories
For drugs with at least one cell line exhibiting a 20% cell viability at higher
doses, which is consistent with a drug response (n=46), we also calculated the
Spearman correlation coefficient between the SBP and TGen response data for
each of the nine concentrations and also across all nine concentrations (Figure
2.2D, Figure 2.2E, Figure 2.6). The correlation coefficients across all available
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Figure 2.1: Differences in HTS plating schemes. Nine 384-well plates are used for
each cell line. Left: TGen/SBP plating scheme. Each plate consists of triplicates
of three doses across 120 drugs and 8 DMSOs. Right: Alternate plating scheme
with each plate including all 9 doses.
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Figure 2.2: A. Pairwise scatterplots across nine drugs comparing SBP 3-point
screen against same three concentrations from SBP 9-point screen. Colors indi-
cate concentration: 0.1 (green), 1.0 (blue), and 10.0 µM (purple). B. Correlation
coefficients from pairwise spearman correlation across same three concentrations.
Colors indicate concentration: 0.1 (green), 1.0 (blue), 10.0 µM (purple), and across
all three concentrations. C. Violin plot of correlation coefficients. D: Violin plot
of correlation coefficients. E. Pairwise analysis of mean Cell Viability across nine
drugs exhibiting at least one CV less than 20%. Gradient indicates concentration
from 0.02 M (light) to 10 µM (dark). Pairwise scatterplots comparing SBP 9-point
HTS against TGen 9-point HTS.
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dosages were greater than 0.0 in 44 out of the 46 drugs (Bonferroni-adjusted p-
value < .05 in 22 of the 44 drugs). Individual pairwise scatterplots for each dose
across the 46 drugs indicate that for a large number of them, there is a high degree
of between-laboratory consistency. As in the three-concentration drug response
analysis performed, the drug responses were more consistent at higher doses and
across all dosages when considered together (Figure 2.2E, Figure 2.6). The stronger
correlation at higher dosages, especially in the context of lower doses that do not
induce an effect or response, reveal technical variation and “noise” that should be
considered in analyses seeking to identify bona fide drug-induced effects producing
signals that rise above this experiment-wise noise. Likewise, the improved corre-
lation coefficients observed when comparing the nine-concentration dose-response
curves (DRCs) against the three-concentration DRCs suggest that a full range of
DRCs may be better at revealing true biological variation in the HTS data.
2.3.3 Comprehensive Analysis Considering the Entire HTS
Experimental Setting via ANOVA Modeling
For a more comprehensive assessment of the factors contributing to the
variation in drug response associated with our HTS studies, we applied flexible
linear regression modeling within an ANOVA context. We ultimately wanted to
partition the variation in cell viability data arising from the entire HTS study into
factors representing different experimental and biological conditions (i.e., across all
plates on which the samples were arranged, drugs, drug concentrations, cell lines,
and laboratories; Supplemental Table 2.1). We limited this analysis to the four
cell lines in common at the two independent laboratories. In order to conduct the
modeling appropriately, we initially had to choose a comparator to be contrasted
with all the other subgroupings for each of the different factors we studied. This was
achieved by creating simple zero (absence) or one (presence) dummy variables for
each factor subgroup. We randomly selected SBP as the comparator laboratory,
Cladribine as the comparator drug, plate 36 (from the SBP experiment) as the
comparator plate, cell line A375 as the comparator cell line, and the lowest dose
(0.02 µM) as the comparator dose. Our analysis found that the laboratory used
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Table 2.2: Percentage of variance explained by the experimental factors.
Df Sum Sq Mean Sq F value Pr(>F) % Variance explained
CellLines 3 1409075 469692 1064.446 < 2.2e-16 4.94
SBP 1 7975 7975 18.0742 2.13E-05 0.03
Ldose 8 1493445 186681 423.0677 < 2.2e-16 5.24
Drug 119 12966053 108958 246.9287 < 2.2e-16 45.46
Plates 65 921052 14170 34.236 < 2.2e-16 3.23
Residuals 25723 11721774 441
explained 0.028% of the variation in drug response, whereas plate (3.23%) and
other biological factors such as drugs (45.5%), concentration (5.24%), and cell
lines (4.94%) explained approximately 60% of the variation (Table 2.2). To identify
the individual factors that were most statistically significant sources of variation,
we carried out simple t-tests on each factors regression coefficient. We used a
conservative Bonferroni-correction to accommodate the multiple tests. The results
suggested that laboratory was only marginally significant factor relative to the
others (Figure 2.3A, Figure 2.7). Analysis of the cell lines indicated that two of
the four cell lines, MeWo and SK-MEL-2, had an effect on drug responses that
were statistically significantly different from the comparator cell line A375. This
could be due to the BRAF mutation status in the cell lines: A375 (the comparator
cell line) and UACC-0257 are cell lines with the BRAF V600E mutation, whereas
MeWo and SK-Mel-2 are BRAF wild type cell lines. Obviously, more work on this
hypothesis is needed before attributing differences to the presence of the BRAF
V600E mutation. Additionally, the higher concentrations (i.e., 2.0, 4.0, and 10.0
µM) were the most statistically significant, consistent with the existence of overall
dose-response relationships in the experiment.
Interestingly, we also found that a large number of SBP plates were mod-
erately statistically different from other plates both used at SBP and TGen; how-
ever, a single TGen plate (plate 25) was highly significant. Furthermore, only one
SBP plate yielded a more significant t-statistic (plate 27) than the TGen plate 25
(Supplemental Table 2.2). As expected, the outlying plates produced DRCs with
greater variability (e.g., Mitoxantrone DRCs for UACC-0257 at 0.1, 1.0, and 10.0
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Figure 2.3: A: Application of flexible linear models, using ANOVA methods, to
explore the variation in CV that is explained by site, cell lines, dose, drug, and
plates. Sites explained a small proportion of the variation, whereas drugs, dose,
and cell lines explained a majority of the variation observed in CV. Nine of the 120
drugs are shown. B. Plots of dose response curves for each of the cell line and site
combinations. For example, greater variance is observed within Mitoxantrone in
concentration from outlying plates detected by ANOVA-like methods. C. Assessing
the variation in CV that is explained by site, cell lines, dose, drug, and drug-site
interaction. To further assess the reproducibility of HTS, we examined the drug-
site interaction terms and found that 19 of the significant drugs did not have a
significant drug-site interaction term.
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µM for SBP plate 27 and at 0.02, 0.2, and 2.0 µM for TGen plate 25, Figure 2.3B).
Although plate-effects explained 3.23% of the variation in cell viability, the small
number of highly significant plates suggests that plate analysis and ways of accom-
modating plate effects in HTS data analyses, or subsequent removal of outlying
plates, should be performed to assess the overall quality of the HTS data and po-
tentially lead to explanations for why some drugs dont replicate across site-specific
studies (e.g., because some plates were outlying and should be removed as opposed
to a more global analysis and rationale). The reasons for plate effects should be
explored, but could reflect contamination, technician, or robot error when setting
up the plate or experiment in question. Importantly, if the drugs, concentrations
and cell lines used on the plate led to biologically meaningful effects, then one
would not be able to separate the biological significance from a potential technical
artifact, which suggests the use of controls and designed plating schemes are neces-
sary. Finally, we found that most drugs in the study exhibited strong, statistically
significant p-values, far beyond what would be expected by chance alone.
2.3.4 Exploring Interaction Effects
To identify whether specific drugs, cell lines, doses, and sites were significant
predictors of drug response (i.e., cell viability) while considering other factors, we
added interaction terms to the linear models. When we accounted for laboratory
x drug interactions, we found that many of the drugs exhibited significant inter-
action term p-values; in fact many more than would be expected by chance alone.
These results indicate that although drugs may influence variation in cell viabil-
ity across the experiment as a whole, some of the cell viability variation may be
laboratory-specific (Supplemental Table 2.3). 19 drugs yielded significant drug p-
values, yet non-significant drug-laboratory interaction effects (Figure 2.3C, Figure
2.8), indicating that these drugs exhibited overtly reproducible effects (Supple-
mental Table 2.4). As expected, when we incorporated the drug x dose interaction
terms into our analysis models, we found that a majority of the variation signifi-
cantly accounted for by dose was limited to higher concentrations, which of course
makes sense (Figure 2.9). Importantly, drug x laboratory interaction effects only
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explained an additional 3.94% of the cell viability variation, whereas drug x dose
interaction effects explained an additional 11.02% of the variation in cell viability.
The consideration of three-way interaction effects led to additional insights
into the factors contributing to cell viability in a pronounced enough way to rise
above the “noise” in cell viability across the HTS experiments as a whole. Lab-
oratory x drug x dose effects explained 2.5% of cell viability variance and drug x
dose x cell line explained 3.6% of the variance (Supplemental Table 2.5). These
findings provided further evidence that laboratory effects were not as influential
on the experiment as a whole relative to other factors. While nine drugs appeared
to have laboratory-specific effects (i.e., a non-significant effect when considering
the drug alone, but a significant drug x laboratory interaction effect), drug x dose
interactions had the largest impact on the drug-associated cell viability, which it to
be expected (Figure 2.10). Again, we identified a subset of drug x dose x cell line
interaction terms that were significant (Supplemental Table 2.6), suggesting that
there may be some heterogeneity among the cell lines (likely due to genetic dif-
ferences) affecting the drug response. This is important in that it suggests unique
cell-line features may indicate efficacy of certain drugs, which is consistent with the
goal of personalized medicine. The significant differences in cell viability across the
cell lines generally appear in the intermediate concentration ranges (Figure 2.11).
2.3.5 Re-analysis With Broader Set of Comparator Drugs
and Cell Lines
To investigate whether the use of an arbitrary drug as the comparator drug
impacted our initial analyses in any way, we set out to identify a group of cell
line and drug combinations that did not exhibit any dose-response or general drug
effect. These combinations would then effectively act as a group of controls whose
cell viabilities represent simple noise and technical variation when compared to
the other cell line-drug combinations. These analyses would allow us to see if
compelling drug or drug x cell line effects can be identified that rise above the
noise and variation exhibited in the HTS experiment as a whole. As noted in the
Methods section, we fit a three-parameter sigmoidal, a four-parameter sigmoidal, a
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linear, and a constant model to each of the cell lines for each drugs and dosages to
characterize dose response curves. We then selected the drug-cell line pairs where
the constant model fit the data the best based on the Akaike Information Criterion
(AIC), since this would be indicative of no evidence of a drug or dose-dependent
response. The set of drug x cell line combinations that suggested no evidence for
a drug or dose-dependent response was then used as the comparator group in a
re-analysis of the cell viability data. The re-analysis suggested that the laboratory
in which the assays were done explained a minimal proportion of the variance
(0.03%). However, drug effects explained 41.2%, dose 5.24%, cell line 4.94%, and
plates 3.23% of the variation in cell viability across the experiment (Supplemental
Table 7). Interestingly, this re-analysis greatly reduced the number of statistically
significant drug effects, suggesting that only a small subset of drugs studied may
be exhibiting actual effects that rise above the noise in cell viability across the
experimental setting as a whole (Figures 12-15 and Supplemental Tables 2.7-2.10).
2.3.6 Comparing the Results of Models that Accommodate
Plate-Specific Effects to Those That Do not
To assess the impact that technically-deficient or outlying plates have on
the interpretation of HTS experiments, we assessed the statistical significance of
the effects on cell viability of each drug in the context of the entire experiment
using our linear model. We used the drugs that did not exhibit evidence for a dose
response relationship as a comparator group, as discussed in the previous section.
When not accommodating any site, plate, and dose (since doses were plated in
triplicates on each plate) effects in the model, we found 54 significant drugs with
drug-effect p-values surpassed Bonferroni-adjusted significance thresholds (Supple-
mental Table 2.11). When the site, plate and dose effects were considered in the
model, we found 44 drugs with drug effect p-values that surpassed Bonferroni-
adjusted significance thresholds (Supplemental Table 11). Strikingly, only 28 of
the 44 drugs (64%) resulting from these analyses were in common, further con-
firming that experimental factors ultimately affect downstream analyses as well
as the interpretation of analyses meant to identify drugs with pronounced effects
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(Supplemental Table 2.11).
2.3.7 Analysis of CCLE and GDSC Data
We used ANOVA analyses on IC50 values provided in the CCLE and GDSC
data sets along with our SBP and TGen data on the four cell lines and six common
drugs they had in common. In these models, we randomly selected CCLE as the
comparator laboratory, the drug Crizotinib as the comparator drug, and cell line
A375 as the comparator cell line. Similar to the analysis comparing the raw SBP
and TGen data, we found that laboratories were not significant predictors of IC50
values when we also accommodated drug, cell line, and laboratory effects in the
model. We note, however, that we did observe some laboratory-specific effects for
one of the six drugs, Nilotinib (Figure 2.4).
2.4 Discussion
Although there has been a considerable amount of interest and development
in HTS technologies, there have been few attempts at standardizing protocols and
ensuring the reliability and reproducibility of the resulting data. Many sources
of variation implicated in HTS studies, such as the laboratory used to pursue the
experiment, technicians, reagents and version of reagents used, plating schemes,
cell culture conditions and dosing ranges, will inevitably have an effect on the
resulting data. However, properly recording and accommodating these factors in
the analysis of HTS data can aide in not only an assessment of the quality of the
data, but also the interpretation of the results.
We sought to quantify the sources of variability in an HTS setting in order to
gauge the, reliability and reproducibility of the resulting data. We did this using
HTS data from a study on melanoma cell lines and simple correlation analyses
coupled with often-used ANOVA modeling methods. The methods we discussed
and applied can be used with any HTS data set including many of those in the
public domain, although many studies have either used methods like we have
proposed or different methods for assessing the concordance between datasets9
25
Figure 2.4: ANOVA analysis on IC50 values from SBP, TGen, GDSC, and CCLE.
Site effects were generally minimal; however, site specific effects were observed in
Nilotinib.
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of all sorts (e.g., gene expression microarray, next generation sequencing, reverse
phase protein arrays, etc.). Using the ANOVA setting, we, for example, identified
evidence that certain plates used in the experiment were problematic and thus
could undermine the reliability of the HTS experiment as whole if not accounted
for properly.
We chose not to construct dose-response curves (DRCs) for each cell line for
each drug and then compare, e.g., IC50 values extracted from those curves across
sites or among different conditions, since this would ultimately ignore variation
introduced by different technical factors impacting dose effects on cell viability
(e.g., plate effects) and hence the DRCs. In this context, once outlying plates
have been identified, it is possible to reassess the reliability of the HTS data using
the traditional methods while excluding those outlying plates (alternatively, one
could obtain coefficients associated with significant experimental effects and weight
them accordingly). Additionally, ANOVA methodology allows for the simultaneous
analysis of all cell viability data across all drugs to identify true and very compelling
signals that have been obtained in a HTS experiment. Although the specific plating
scheme in our experiments (Figure 2.1) allowed for the simultaneous analysis of
various factors, it could also lead to confounding effects between plate and dose
because triplicate concentrations were constrained to individual plates (i.e., one
of three concentrations sets were used for each plate: concentrations 1, 4, and 7;
concentrations 2, 5, and 8; and concentrations 3, 6, and 9).
In terms of specific findings, we observed that laboratory effects only ex-
plained a small fraction (0.03%) of the cell viability variation in our HTS setting.
This contrasts with the results of studies described in recent publications about
the reliability of the data associated with two very large cancer cell line screens
pursued by different groups at different sites [Barretina et al., 2012] [Yang et al.,
2013] [Krogan et al., 2015] [The CCLE and The GDSC Consortiums, 2015]. We
also observed that the main source of variation in our study could be attributed to
the drugs used further indicating that in certain settings, HTS data may indeed
be reliable. By considering site x drug interactions in our analyses, we identi-
fied drugs with reproducible effects. Our consideration of three-way interaction
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terms allowed us to identify some heterogeneity among the cell line response to
drugs, suggesting that genetic differences among cell lines may explain why some
cell lines are responsive to certain drugs. This is consistent with the notion that
in vitro drug screening can shed light on the potential for personalized medicine
[Crystal et al., 2014]. We also find that the downstream analyses of drug as-
sociation tests are greatly impacted by whether one accommodates or does not
accommodate experimental and technical factors, such a plating scheme, in the
analysis models. In this light, we found that many of the drugs identified without
experimental factors were false positives. Similarly, we find that many drugs that
were significantly associated with drug response were missed when the models did
not accommodate experimental factors. Our experience suggests that interaction
terms in ANOVA-like analysis settings should be considered in order to tease out
important and compelling drug associations that would otherwise go undetected
due to the masking of particular drug effects by “noise.”
Ultimately, assessing the variability, reliability and reproducibility of HTS
data by designing the study to contrast different experimental conditions could add
to the overall experimental costs. As a result, alternative methods that can ac-
count for sources of variation are needed. Our analysis at the very least highlights
the importance of using consistent dosing and plating schemes that include spe-
cific controls, which would allow researchers to not only measure and test for the
impact of experimental factors on the outcomes, but also adjust for these specific
experimental effects when making claims about, e.g., drug and cell-line specific ef-
fects. Thus, ANOVA-like methods can accommodate different experimental factors
that may influence the HTS assays in pronounced ways and also reveal compelling
signals attributable to drugs and experimental compounds. Although our analysis
was performed only within the context of melanoma, and, importantly, only within
the context of four melanoma cell lines and 120 drugs, our overall ANOVA-based
approach can be used to reassess the quality of publicly available data as well as
additional HTS data.
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2.5 Materials and Methods
2.5.1 Data
We initially performed a nine-concentration (i.e., dose) HTS study (drug
concentrations: 0.02, 0.04, 0.1, 0.2, 0.4, 1.0, 2.0, 4.0, and 10.0 µM) on 40 melanoma
cell lines across 120 drugs (Table 2.1) at Sanford Burnham Prebys Medical Dis-
covery Institute (SBP). We used 384-well plates with three concentrations of a
drug assigned to each plate across all 120 drugs in triplicate (Figure 2.1). Drugs
were spotted on 384-well clear bottom tissue culture treated plates (Greiner Bio-
One, #781098) using an Echo Liquid Handler (Labcyte Inc., Sunnyvale, CA) such
that addition of 25Ls of cells (100k cells/mL in RPMI +10% FBS +Pen./ Strep./
Glut., Omega Scientific, Tarzana, CA) resulted in the above described final drug
concentrations and 2.5k cells/well. Upon plating, the cells were gently spun down
at 1k rpm for one minute and incubated with drugs for 96 hours at 37 ◦C in a
standard tissue culture incubator. After this time course, plates were allowed to
equilibrate to room temperature for 30 minutes before 10 µLs per well of freshly
prepared CellTiterGlo reagent (G7571, Promega Corp., Madison WI) were added.
Samples were incubated for ten minutes with gentle agitation (100 rpm) before
luminescence was read on a BioTek Synergy2 plate reader using Gen5 software
(BioTek, Winooski, VT).
Each plate was assayed in triplicate and included 24 vehicle only DMSO
controls. In total, nine plates were used for each cell line. For each cell line, drug,
and drug concentration combination, cell viability (CV) measures were obtained
post drug administration and were normalized to the plate-specific average DMSO
cell:
CVnorm = 100 ∗ CellCountDrug/CellCountDMSO
We also pursued an independent three-concentration HTS study (drug con-
centrations: 0.1, 1.0, and 10.0 µM) at SBP across 30 melanoma cell lines (29 in
common with the nine-point screen) on all 120 drugs as described above. Finally,
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we performed the primary nine-concentration HTS study across all 120 drugs for
four melanoma cell lines in common with the initial nine-point SBP screen (four
screened cell lines: UACC-0257, MeWo, SK-Mel-2, and A375) at the Translational
Genomics Research Institute (TGen). For the TGen HTS study, the experimental
protocols were similar to the SBP screen, with minor differences. Specifically, the
compounds were pre-spotted to white, solid-bottom 384-well assay plates (Greiner
Bio-One) using ATS (Biosero, San Diego, CA). Additionally, prior to measuring
the luminescence using an Analyst GT plate reader (Molecular Devices, Sunnyvale,
CA), 25 µL CellTiterGlo reagent (G7571, Promega Corp., Madison WI) was added
to assay plates and incubated at room temperature for one hour (as opposed to
ten minutes at SBP).
MeWo and A-375 cell lines were obtained directly from American Type
Culture Collection, all SK- cell lines were received directly from Memorial Sloan
Kettering Cancer Center, TGen generated all UACC- cell lines, and all were of
low passage number. Cells were maintained according to the manufacturer’s or
collaborators instructions: A-375 cells are grown using DMEM medium, MeWo
and Sk-Mel-2 cells are grown using EMEM medium, and UACC-0257 cells are
grown using RPMI1640 medium. All media have 10% FBS and 1%AA added to
final growth media. All cell lines were banked at low passages in multiple aliquots
as liquid nitrogen stocks to reduce risk of phenotypic drift. All cells were cultured
for less than three months before reinitiating culture from the frozen stock. All
cells were routinely inspected for identity by morphology and growth curve analysis
and validated to be mycoplasma free. All cell lines were free of contaminants.
2.5.2 Data Analysis
We assessed the variability of the HTS data by first examining the corre-
lations between measures obtained at matching doses using the two SBP screens
(i.e., nine-concentration and three-concentration screens) and then across the SBP
and TGen screens (i.e., the two nine-concentration screens). We calculated the
Spearman correlation of the CVnorm between the data obtained from each experi-
mental pair setting at each dose (i.e., single concentration pairs) and the correlation
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coefficient across all available doses (i.e., all three-concentration doses when com-
paring the two SBP screens or all nine-concentration doses when comparing SBP
and TGen screens). Since the Spearman correlation is robust to outliers, is non-
parametric, and does not necessarily assume linear relationships, we chose use it
as implemented in base stats package in R. We assessed the normality of the data
using Shapiro-Wilk test in the base stat package for R.
For a more comprehensive assessment of the assays variability and reliabil-
ity on the four common cell lines across institutes, we used flexible linear models
and ANOVA (also within the base stats11 package in R) to simultaneously assess
drug effects (across all drugs) as well as all other experimental (e.g., plate and
lab) and biological (e.g., drug, dose, and cell line) factor effects by creating (0,
1) dummy variables for each factor (e.g., we had 120-1=119 dummy variables for
the drugs, 9-1=8 for doses, 4-1=3 for cell lines, 72-1=71 for plates, and one for
site). After combining the lab, plate, drug, dose, and cell line factors, there were a
total of 202 factor effects. Notably, we performed a multi-factorial analysis in an
unbalanced experimental design. Under this approach, ANOVA in the context of
linear regression models was used to assess the proportion of variation that can be
attributed to each factor (e.g., laboratory, plate, drug, dose, and cell line). Interac-
tion terms between the factors were also used to assess the non-additive influence
and combinations of different factors. We then fit dose-response curves (DRCs)
to each of the SBP and TGen nine-concentration HTS experiments using four
separate models: a four-parameter sigmoidal model, a three-parameter sigmoidal
model, a linear model, and a constant model (i.e., no dose-response effect). We fit
these DRCs using the nplr package in R. We used the Akaike Information Criterion
(AIC) from the base stats package in R to identify the “best” model for each cell
line and drug combination. The AIC provides an assessment of model performance
while considering the number of parameters used for the model. Thus, this ap-
proach allowed us to assess the fit of each model while adjusting for the number
of parameters assumed within those models. We did this to identify individual
drugs that exhibited no evidence of a dose-response relationship. The drugs and
cell lines that exhibited no evidence of a dose response effect were then treated as
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a set of controls for the other drugs because the variation they exhibited across
the different doses reflect noise-induced and technical variation. We used this set
of control drug-cell line combinations in re-analysis with the ANOVA model, cod-
ing the controls as the baseline drug (i.e. for the “controls”, binary variables for
each drug were set to 0 in the model). To evaluate the impact of controlling for
plate-specific effects, we performed drug association tests using linear models with
interaction terms. We compared models that included and excluded plate effects.
The significance of each drugs effects in the context of the entire experiment was
determined based on a Bonferroni-adjusted significance threshold.
Because we were unable to access the raw experimental data for the Cancer
Cell Line Encyclopedia (CCLE) data, we explored the consistency of the IC50 val-
ues provided from the CCLE5 repository along with IC50 values from the Genomics
of Drug Sensitivity in Cancer6 (GDSC) data repository. We also computed the
IC50 values from our SBP and TGen data using three-parameter sigmoidal curve
fits. The four cell lines in common between the SBP and TGen data sets were also
available for the CCLE and GDSC data, but only six drugs were in common. Fur-
ther, replicates were only available in the GDSC dataset, plating schemes used be-
tween the sites were inconsistent, and there were differences in dose-concentrations
between same cell line and drug combinations from the various datasets. Neverthe-
less, we explored the variation in the HTS data using information on the different
sites (n = 4), cell lines (n = 4), and drugs (n = 6). All analyses were performed
in R and all figures were generated using the graphics package in R.
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2.7 Supplemental Figures
Figure 2.5: Pairwise scatterplots across all 128 drugs comparing SBP 3-point
screen against same three concentrations from SBP 9-point screen. Colors indicate
concentration: 0.1 (green), 1.0 (blue), and 10.0 µM (purple).
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Figure 2.6: Pairwise analysis of mean Cell Viability across 46 drugs exhibiting
at least one CV less than 20%. Gradient indicates concentration from 0.02 µM
(light) to 10 µM (dark).
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Figure 2.7: Application of flexible linear models, using ANOVA methods, to
explore the variation in CV that is explained by site, cell lines, dose, drug, and
plates. Sites explained a small proportion of the variation, whereas drugs, dose,
and cell lines explained a majority of the variation observed in CV.
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Figure 2.8: Assessing the variation in CV that is explained by site, cell lines, dose,
drug, and drug-site interaction. To further assess the reproducibility of HTS, we
examined the drug-site interaction terms and found that 19 of the significant drugs
did not have a significant drug-site interaction term.
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Figure 2.9: Assessing the variation in CV that is explained by site, cell lines, dose,
drug, and drug-dose interaction. We find that many of the significant drug-dose
interaction terms were from higher concentrations, indicating that a majority of the
variation significantly accounted for by dose was limited to higher concentrations.
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Figure 2.10: Assessing the variation in CV that is explained by site, cell lines,
dose, drug, and 3-way interaction terms. Site-by-drug-by-dose effects explained
2.49% of cell viability variance.
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Figure 2.11: Assessing the variation in CV that is explained by site, cell lines,
dose, drug, and 3-way interaction terms. Drug-by-dose-by-cell line explained 3.6%
of the variance.
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Figure 2.12: Re-assessing the variation in CV that is explained by site, cell lines,
dose, and drug when using AIC-defined control drugs. Results were similar from
using random baseline drug in terms of proportion of variation explained by sites,
cell lines, dose, and drug. However, a smaller number of statistically significant
drug effects were observed.
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Figure 2.13: Re-assessing the variation in CV that is explained by site, cell lines,
dose, drug, and dose-drug interaction when using AIC-defined control drugs.
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Figure 2.14: Re-assessing the variation in CV that is explained by site, cell lines,
dose, drug, and site-dose-drug interaction when using AIC-defined control drugs.
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Figure 2.15: Re-assessing the variation in CV that is explained by site, cell lines,
dose, drug, and cell line-dose-drug interaction when using AIC-defined control
drugs.
Chapter 3
An Additional Example of
Quality Control Analyses for
Drug Screening and Drug Target
Validation Involving Longevity in
Model Species
3.1 Abstract
Model species have been used to identify drugs and drug targets that delay
the onset of age-associated diseases and promote longevity. “Forward pharma-
cology” approaches are used routinely when compounds screened on a large scale
impact lifespan in a model species amenable to high-throughput characterization
such as yeast or Caenorhabditis elegans [Powers et al., 2006] [Park et al., 2011]
[Torres et al., 2013] [Ye et al., 2014] [Miller et al., 2007]. The genes that emerge
from these studies are then subjected to various manipulations or drug targeting
studies to see if those manipulations impact longevity [Miller et al., 2007] [Strong
et al., 2008] [Harrison et al., 2009] [Miller et al., 2011].
Under this approach, quality control issues arise and must be dealt with
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overtly to avoid false positive and false negative results. Similar to high through-
put studies in cancer, screens involving large contrasts among responses to different
drugs potentially affecting longevity of a single species are likely to include exper-
imental “noise” (e.g., inter- and intra- lab variability — plate effects, etc.). If not
carefully modeled and quantified, these factors could potentially affect and bias
the downstream association tests. In the following, methods are discussed that ad-
dress the aforementioned concerns in large-scale drug screening studies involving
C. elegans.
3.2 Introduction
Model organism and in vitro studies are used in various settings to under-
stand human biology, especially in the contexts of drug response and drug targeting
studies. Given ethical restraints and limited resources for human clinical trials, in
vitro models are often desirable and effective substitutes. However, in vitro stud-
ies, even in ideal laboratory conditions, may not reveal drug response patterns
translatable to humans in vivo. In light of this fact, animal models have been
subject to increasing scrutiny [Aitman et al., 2011] [Warren et al., 2016]. Animal
models that facilitate the identification of human biological factors and drugs in-
clude studies of disease mechanisms [Jubb et al., 2016], drug candidate screens [Ye
et al., 2014] and associations with longevity [Warner, 2006]. For example, in the
context of cancer, xenograft models are now routinely used to study disease mech-
anisms and to characterize DNA levels, RNA levels, and even differential protein
expression patterns — all to shed light on mechanisms that influence anti-tumor
drug response. In addition, model organism-based high throughput drug screens
are often used to simulate human disease conditions so that sensitivity and re-
sistance to drugs designed to treat those conditions can be studied. Ultimately,
animal models have the potential to uncover mechanisms impacting drug response
that would be otherwise unattainable in human studies. Further, any biological
and technical limitations in such studies are probably less significant than those in
purely in vitro studies.
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The use of model organisms in studies of longevity has a long and somewhat
complicated history. To evaluate drugs that might affect lifespan, model organisms
with relatively short life expectancies can be used to both minimize the duration
of drug investigative studies and maximize the number of drugs tested. But any
results suggesting strong associations between increased lifespan and particular
drugs should account for and accommodate “noise” before expending additional
valuable resources and especially before involving human subjects. As an example,
in a recent study involving Caenorhabditis elegans, 57 compounds were actually
found to increase longevity [Ye et al., 2014] [Carretero et al., 2015]. However,
the analyses pursued to identify these compounds did not quantify or account for
experimental variability which potentially impacted the results. As a result, we
obtained the raw data from this study in order to assess the proportion of variation
in the drug response outcomes that could be attributed to technical variation,
such as the specific plating of the experiments. Based on our findings, we then re-
evaluated the drugs and compounds considered in the study while accommodating
and quantifying the experimental and biological sources of variation.
In the following, I describe our experiences and results trying to accom-
modate sources of variation in the large-scale drug screening study involving C.
elegans. Based on our experience, care must be taken in studies like these going
forward if compelling insights into drugs and drug targets affecting lifespan are to
be obtained.
3.3 Materials and Methods
3.3.1 Caenorhabditis elegans Data Acquisition and Anal-
ysis
In collaboration with The Scripps Research Institute (TSRI), we obtained
data on Caenorhabditis elegans from a previous study conducted by Michael Pe-
trascheck [Ye et al., 2014] [Rangaraju et al., 2015b] [Carretero et al., 2015] [Ran-
garaju et al., 2015a]. The data consists of 1280 different compounds that are
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grouped into pharmacological classes according to their mammalian targets. This
commercial collection of pharmacological agents with known or suspected tar-
gets in humans is known as the Library of Pharmacologically Active Compounds
(LOPAC). As described in Petrascheck’s published results, animals were grown
in liquid medium at 20 ◦C in 96-well plates with 5-15 animals per well [Ye et al.,
2014] [Rangaraju et al., 2015b] [Carretero et al., 2015] [Rangaraju et al., 2015a].
Then, the animals were treated with either 33µM concentration of a drug or vehi-
cle control (.33% DMSO). From the 1280 LOPAC drug screen, we obtained plate
IDs; row and column specifications; drugs treated; pharmacological classes; and
number of animals alive, dead, and days alive.
For each drug, we converted the number of animals alive and dead into
a fraction of C. elegans alive. Then, using this fraction of C. elegans as the
dependent variable, we applied multiple linear models to assess the proportion of
variation explained by creating (0, 1) dummy variables for each experimental and
biological factor (e.g., we had 1281-1 = 1280 dummy variables for the drugs; 56-1
= 55 for the pharmacological class; 16-1 = 15 for the plates, 12-1 = 11 for plate
column; 8-1 = 7 for plate rows; 4-1 = 3 for replicates; and 2-1 = 1 for DMSO). For
each set of factors, we also needed to specify the reference factor — we chose the
control drug (DMSO only), the Vanilloid pharmacological class, plate 1, column
1, row 1, replicate 1, and DMSO 1. This approach allowed us to measure the
influence of experimental factors and potential plate-specific outliers (e.g., entire
plates, rows, columns, and row x column interaction terms). Additionally, these
linear models allowed us to identify candidate drugs after accommodating these
sources of variation. For example, we used interaction terms between days and
drugs in order to identify drugs that potentially modulate lifespan. Significance
was reassessed under these models and p-values were adjusted using Benjamini
Hochberg FDR procedures [Benjamini and Hochberg, 1995]. We then compared
significant drug candidates and pharmacological classes against the results from
the previously published manuscript [Powers et al., 2006].
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3.4 Results
3.4.1 Caenorhabditis elegans Screening Study
3.4.1.1 Assessing Sources of Variation in Caenorhabditis elegans
Longevity Study
To ascertain the impact of experimental factors on the sources of variation
in the study, we fitted linear models with only experimental factors and associated
interaction terms. We found that the combined covariates and interaction terms
explained about .35% of the variation (Table 3.1). Although none of the groups
significantly affected the variation in the data, plots of the individual factors did
reveal that there might have been an outlying column (Figure 3.1), suggesting that
shifts within specific columns should be accounted for prior to making claims about
observations. We then re-assessed the significance for the plate effects while includ-
ing column x row interaction terms (Figure 3.2). Although none of the factors nor
interaction terms produced p-values beyond a bonferroni adjusted threshold, we
again found that column 10 produced strong p-values associated with the fraction
of C. elegans alive. Moreover, the plots of the p-values indicated that these plate-
effects were mainly attributable to three rows (3, 5, and 8) within the plate. In
light of the interaction terms, we also noticed other potential experimental outliers
(e.g., column 9 x row 3). These results provided further arguments that experi-
mental factors — such as plate, column, row, and experimental site — should be
included in the analyses of HTS studies.
3.4.1.2 Reassessing Candidate Longevity Drugs and Pharmacological
Classes
To assess the potential impact of experimental factors on association tests,
we reanalyzed the LOPAC drugs and pharmacological classes used in the study.
Unlike previous methods, we performed association tests in the context of the
overall study. However, when we analyzed the drugs, we could not use row x
column interaction terms due to singularity issues (Table 3.2). To identify can-
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Table 3.1: Assessing the proportion of variation in experimental data explained
by each of the experimental factors, including column x row interaction terms.
Significance codes for F statistics: p-val < .05 (’*’), p-val < .01 (’**’), p-val < .001
(’***’)
DF Sum Sq Mean Sq F Value Pr(> F) Sig % Var Explained
Plate 15 2.8 0.18571 1.9608 0.01424 * 0.05%
Column 11 3.5 0.3226 3.4063 9.65E-05 *** 0.06%
Row 7 4.6 0.65047 6.8682 3.47E-08 *** 0.08%
Replicate 3 0.2 0.06608 0.6978 0.55328 0.00%
DMSO 1 0.3 0.2546 2.6883 0.10109 0.01%
Column:Row Interaction 77 9 0.11663 1.2314 0.08229 . 0.16%
Residuals 60806 5758.8 0.09471 99.65%
Figure 3.1: Plot of −log10 p-values for each experimental factor against the ob-
served fraction of C. elegans alive. Vertical bars represent each group of factors
analyzed with ANOVA.
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Figure 3.2: Plot of −log10 p-values for each experimental factor, including column
x row interaction terms, against the observed fraction of C. elegans alive. Vertical
bars represent each group of factors analyzed with ANOVA.
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Table 3.2: Assessing the proportion of variation in experimental data explained by
each of the experimental factors, drugs, and days (including drug x day interaction
terms). Significance codes for F statistics: p-val < .05 (’*’), p-val < .01 (’**’), p-val
< .001 (’***’)
DF Sum Sq Mean Sq F Value Pr(> F) Sig % Var Explained
Plate 15 2.79 0.19 3.8812 5.14E-07 *** 0.05%
Column 11 3.55 0.32 6.7423 2.00E-11 *** 0.06%
Row 7 4.55 0.65 13.5947 <2.2e-16 *** 0.08%
Drug 1270 171.41 0.13 2.8209 <2.2e-16 *** 2.97%
Days 1 2624.12 2624.12 54843.4665 <2.2e-16 *** 45.41%
Replicate 3 0.33 0.11 2.2749 0.077713 . 0.01%
DMSO 1 0.42 0.42 8.8777 0.002888 ** 0.01%
Drug:Days Interaction 1280 180.89 0.14 2.9536 <2.2e-16 *** 3.13%
Residuals 58332 2791.04 0.05 48.30%
didate drugs for modulating lifespan, we also included interaction terms between
days and drugs. After performing Benjamini Hochberg FDR corrections on the p-
values for the drugs, we found only two drugs significant at an alpha level of .05 —
Se(methyl)selenocysteine hydrochloride (adjusted p-value 0.00045) and Tyrphostin
A9 (adj p-value 0.025). Strikingly, these two drugs were not reported as candidate
longevity drugs in the original manuscript [Powers et al., 2006]. Upon relaxing the
stringencies of the p-value threshold, we recovered two additional drugs that were
significant in the original manuscript (Pergolide methanesulfonate and Phorbol
12-myristate 13-acetate; adj p-val .0996). However, when we evaluated significant
drug x day interactions, we found 74 drugs significant (15 in common with previ-
ous findings) at the FDR adjusted p-value threshold of .01 and an additional 57
drugs significant (seven in common with previous findings) at the FDR adjusted
p-value threshold of .05.
When analyzing the pharmacological class, we included row x plate interac-
tion terms (Table 3.3). In these analyses, we were able to recapitulate the results
from previous studies and found both Dopamine and Phosphorylation pharmaco-
logical classes to be highly significant (FDR adj p-val < 2.46e-45).
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Table 3.3: Assessing the proportion of variation in experimental data explained
by each of the experimental factors, pharmacological classes, and days (including
pharmacological class x day interaction terms). Significance codes for F statistics:
p-val < .05 (’*’), p-val < .01 (’**’), p-val < .001 (’***’)
DF Sum Sq Mean Sq F Value Pr(> F) Sig % Var Explained
Plate 15 2.8 0.19 3.3982 8.39E-06 *** 0.05%
Column 11 3.5 0.32 5.9032 1.12E-09 *** 0.06%
Row 7 4.6 0.65 11.9029 2.97E-15 *** 0.08%
Replicate 3 0.2 0.07 1.2092 0.3046 0.00%
DMSO 1 0.3 0.25 4.659 0.0309 * 0.01%
Pharmaco Class 53 9.1 0.17 3.1341 1.44E-13 *** 0.16%
Days 1 2382.4 2382.4 43595.4136 <2.2e-16 *** 41.22%
Column:Row Interaction 77 24 0.31 5.6917 <2.2e-16 *** 0.42%
Pharmaco Class:Days Interaction 55 35.4 0.64 11.7623 <2.2e-16 *** 0.61%
Residuals 60697 3317 0.05 57.39%
3.5 Discussion
Model organism studies have the potential to alter the pharmacological
landscape, especially in the context of age association studies. However, issues
exist organism-specific experiments. In species-specific HTS studies, we observed
plate-specific effects that impact the downstream longevity association analyses.
Upon accounting for these experimental factors, the overall pharmacological classes
identified were the same, but we identified a large set of drugs associated with
longevity that were not previously reported. Of the 57 previously identified drugs,
our analysis identified 22 of the compounds after correcting for experimental effects
and multiple hypothesis testing. Although the sets of analysis were vastly different
— ours considered drug associations in the context of the overall screen, while
previous methods used individual replicates and subsequent merging of results
— it is difficult to reconcile the differences between these results without further
experiments on candidate drugs. Still, these results suggest that experimental
“noise” should be carefully considered and accounted for prior to downstream
analyses and interpretation.
Our analyses highlight some of the common quality control issues faced
when performing model organism studies. We accommodate these issues through
the use of statistical and computational approaches. However, these methods
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require careful record keeping of experimental factors so that they can be included
as factors in downstream analyses.
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Chapter 4
Nonlinear Mixed Effects Models
for Use in High Throughput Drug
Screens: Applications to
Melanoma Cell Line Analysis
4.1 Abstract
Cancer cell lines are used often in high throughput drug screens (HTS) to
explore the relationship between characteristics of the cell lines (e.g., their genetic
profiles) and responsiveness to different compounds and drugs. Many current anal-
ysis methods used to draw inferences about such relationships focus on one aspect
of drug-specific dose-response curves (DRCs) obtained from the cell lines, the con-
centration causing 50% inhibition of a phenotypic endpoint (IC50), that is often
estimated in isolation from a small number of doses and responses gathered on each
cell line. Such analysis methods do not consider properties of DRCs that might not
be captured by IC50 values, nor do they leverage information about drug response
patterns estimated with the different cell lines simultaneously, which could lead to
increased false positive and false negative rates in drug response associations. We
consider the application of two methods, each rooted in nonlinear mixed effects
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(NLME) models, that test the relationship relationships between estimated cell
line DRCs and factors that might mitigate response. Both methods leverage esti-
mation and testing techniques that consider the simultaneous analysis of different
cell lines to draw inferences about any one cell line. One of the methods is de-
signed to provide an omnibus test of the differences between cell lines DRCs that
is not focused on any one aspect of the DRCs (such as the IC50 value). We simu-
lated different settings and compared the different methods on the simulated data.
We also compared the proposed methods against traditional IC50-based methods
using 40 melanoma cell lines whose transcriptomes, proteomes, and, importantly,
BRAF and related mutation profiles were available. Ultimately, we find that the
NLME-based methods are more robust, powerful and, for the omnibus test, more
flexible, than traditional methods. Their application to the melanoma cell lines
reveals insights into factors that may be clinically useful.
4.2 Introduction
Cancers have proven notoriously difficult to treat because of their cellu-
lar complexity and heterogeneity, their ability to coopt a number of naturally-
occurring molecular processes and factors to sustain their growth, their capacity
to evade and adapt to treatments through a rapid evolution, and a general lack of
available drugs that can combat different mechanisms contributing to their initi-
ation and growth. The identification of specific factors and processes that reveal
points of vulnerability in cancers should reveal therapeutic targets, but relevant
strategies for doing so are far from trivial. In addition, there is now growing con-
sensus that the factors contributing to the initiation and growth of a tumor are
nuanced and often very individual-specific, so that the best way to treat cancer is
to identify the potentially unique determinants of an individuals tumor and ther-
apeutically target those determinants. Such “personalization” efforts for cancer
treatments are receiving a great deal of attention [Garraway et al., 2013] [Shrager
and Tenenbaum, 2014].
Strategies for identifying the very heterogeneous determinants of cancer
56
that might be used in the tailoring therapies to an individual are varied. Many
large-scale epidemiological and tumor characterization efforts, such as the The
Cancer Genome Atlas (TCGA) [The Cancer Genome Atlas Research Network
et al., 2013] initiative, have proven to be useful but suffer from quality control
and inadequate sample size issues [Buckley et al., 2016]. Strategies that consider
testing different treatment regimens on individual patients until an effective ther-
apy is found — which is often what happens spontaneously in the clinical care
of patients refractory to initial treatments — is problematic from both biological
and ethical standpoints, since purposely using a drug that might be known to be
ineffective simply to test another drug is unethical. In addition, drugs have effects
on tumors that change their composition, as noted, which could thwart the logic
behind attempts to switch a patient to a pre-specified list of drugs [Schork, 2015].
Alternatives to large-scale epidemiological and focused clinical studies on
individual patients to find ways of identifying connections between drugs and tumor
characteristics include tumorgraft (or xenograft) models and tumor cell line-based
studies. Implanting tumors in mice or other organisms and studying the engrafted
tumors response to drugs has been used to great effect, but depends critically on
the tumor environment in mice mimicking that in humans, which is not often the
case [Lum et al., 2012] [Monsma et al., 2012]. Cell line based models derived from
actual patient tumors have been used, also to great effect, for some time [Barretina
et al., 2012] [Yang et al., 2013]. They are relatively easy and inexpensive to perform
and can be used in high-throughput drug screening protocols (HTS), making them
especially attractive for gaining at least initial insights into what drugs might be
most effective against cells making up a tumor. Cell line models do suffer from the
problem of extrapolating their in vitro responses to actual in vivo settings [Gillet
et al., 2013], but their aforementioned ease of use and amenability to HTS makes
them particularly attractive [Wang et al., 2016]. In addition, emerging strategies
for creating cell lines using, e.g., induced pluripotent stem (iPS) cells, have added
to their sophistication [Mercola et al., 2013].
Unfortunately, the reproducibility of cell line-based HTS experiments have
been called into question [Haibe-Kains et al., 2013]. Differences in protocols used,
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the media within which the cells are suspended, the precise formulation of the
drugs used in the screening, the origins of the cell lines used, among other items,
can create differences in outcome of studies involving what are thought to be the
same cell lines. It is arguable that many of these technical sources of variation in
cell line-based HTS studies can be identified and possibly controlled for in well-
designed experiments [Ding et al., 2017]. However, the analytical methods used
to draw inferences about the relationship between a subset of cell lines observed
dose-dependent responses to a drug and characteristics of those cell lines (e.g.,
their genomic, transcriptomic, or proteomic profiles) also play an important (and
often overlooked) role in the identification of factors that might mitigate a tumors
response to a drug.
Traditional statistical methods for analyzing cell line-based HTS data in-
volve fitting (often sigmoidal) dose response curves (DRCs) to each cell lines dose
response data in isolation and then extracting a single estimated parameter, the
concentration causing 50% inhibition of a phenotypic endpoint, like the cell growth,
(i.e., the “IC50”) value, from those curves [Haibe-Kains et al., 2013] [The CCLE
and The GDSC Consortiums, 2015] [Shoemaker, 2006]. These IC50 values are then
tested for association with other factors, like the expression levels of genes mea-
sured on those cell lines, to identify markers of response. Analyzing each cell line
and drug combination in isolation is highly problematic since it ignores variation
exhibited across the cell lines that might inform the response profile of any single
cell line. Leveraging variation across all the cell lines when making claims about
drug responsive in any single cell line can reduce noise and lead to more reliable
inferences.
In this light, we considered the use of non-linear mixed effects (NLME)
models in analyzing HTS dose-response data, which considers variation across the
data on all or sets of the cell lines in order to estimate and assign a metric of
drug responsiveness to each cell line. We considered two different NLME-based
tests to compare to traditional methods. Both tests considered the evaluation
of the cell lines collectively when estimating IC50 values and other DRC-related
parameters. One test focuses exclusively on the IC50 values estimated from the
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cell lines simultaneously and hence is similar to traditional methods that focus on
IC50 values, whereas the other test leverages a Likelihood Ratio (LR) formulation
of an omnibus test of differences in DRC profiles among groups of cell lines and
is thus much more flexible in theory than IC50-based tests since it can capture
differences between the DRCs among subgroups of cell lines beyond IC50 values.
We applied the proposed NLME-based models and tests to 40 available
melanoma cells lines with genomic, transcriptomic, and proteomic profiles avail-
able that had been screened against 120 drugs. We compared the results of anal-
yses obtained with traditional, IC50-based data analytic methods to the proposed
NLME-based methods. We also considered analyses with the available Cancer
Cell Line Encyclopedia [Garraway et al., 2013] [Barretina et al., 2012] (CCLE)
data sets, and performed simulation studies to explore the relative advantages of
each method in different situations that go beyond those focusing on IC50 values.
We find that the proposed NLME-based tests are more powerful, sensitive and, for
the omnibus test, flexible than traditional methods. In fact, the LR-based NLME
test can be used to uncover associations among various factors collected on the
cell lines, such as gene expression levels, and drug responsiveness in a very robust
and compelling way, and that are simply beyond the reach of analyses focusing
exclusively on IC50 values. Both proposed methods may reveal factors mitigat-
ing cancer drug response that could inform personalized or targeted therapeutic
approaches to cancer in actual patient care.
4.3 Materials and Methods
We made use of a number of resources in our evaluation of different methods
for analyzing cell line-based DRC data generated from HTS data. We briefly
describe these resources before providing greater detail about the construction
and execution of the two proposed NLME-based models and tests.
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4.3.1 Cell Lines
Thirty-three melanoma cell lines from the University of Arizona Cancer
Center (UACC) repository were used for our analyses. Additionally, the SK-MEL-
2 cell line was received directly from Memorial Sloan Kettering Cancer Center
through the Cancer Cell Line Encyclopedia (CCLE) repository and MeWo cell line
from the Developmental Therapeutics Program’s NCI-60 repository. The Transla-
tional Genomics Research Institute (TGen) had access to all other UACC-cell lines
through the UACC [Ding et al., 2017]. All cell lines were of low passage number.
Cells were maintained according to the manufacturer’s or collaborators instruc-
tions. All media used to grow and harvest the cell lines had 10% FBS and 1% AA
added to final growth media, and all cell lines were banked at low passages in mul-
tiple aliquots and liquid nitrogen stocks to reduce risk of phenotypic and genetic
drift. All cells were cultured for less than three months before reinitiating culture
from the frozen stock, were routinely inspected for identity by morphology and
growth curve analysis and validated to be free of mycoplasma and contaminants.
4.3.2 Drug Screening
Each of the 40 cell lines was used in a nine-point (i.e., concentration/dose)
HTS study (drug concentrations: 0.02, 0.04, 0.1, 0.2, 0.4, 1.0, 2.0, 4.0, and 10.0
µM) across 120 drugs (Figure 4.1A, Table 4.3) at the Sanford Burnham Prebys
Medical Discovery Institute (SBPMDI or SBP in the sequel). Drugs were spotted
on 384-well clear bottom tissue culture treated plates (Greiner Bio-One, #781098)
using an Echo Liquid Handler (Labcyte Inc., Sunnyvale, CA) such that addition of
25µLs of cells (100k cells/mL in RPMI +10% FBS +Pen./ Strep./ Glut., Omega
Scientific, Tarzana, CA) resulted in the above-described final drug concentrations
and 2.5k cells/well. Upon plating, the cells were gently spun down at 1k rpm for
one minute and incubated with drugs for 96 hours at 37 ◦C in a standard tissue cul-
ture incubator. After this time course, plates were allowed to equilibrate to room
temperature for 30 minutes before µLs per well of freshly prepared CellTiterGlo
reagent (G7571, Promega Corp., Madison WI) were added. Samples were incu-
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bated for ten minutes with gentle agitation (100 rpm) before luminescence was read
on a BioTek Synergy2 plate reader using Gen5 software (BioTek, Winooski, VT).
Each plate was assayed in triplicate and included 24 vehicle-only DMSO controls.
4.3.3 Gene Expression Assays
The cell line samples were subjected to nucleic acid extraction, verifica-
tion, amplification, and hybridization per the protocol regarding the use of the
Affymetrix HG-U133 plus 2.0 arrays (54,675 probesets, Affymetrix, Santa Clara,
CA). Affymetrix HG-U133 Plus 2.0 microarrays were normalized (background ad-
justment, interquartile normalization, and median polish) using robust multichip
averaging [Irizarry et al., 2003] in R.
4.3.4 Phosphoproteomic Assays
Cell lysates from the cell lines were printed in triplicate onto nitrocellulose-
coated slides (Grace Bio-Lab, Bend, OR) using a 2470 Aushon arrayer equipped
with 185 µm pins (Aushon BioSystems, Burlington, MA) and subjected to Re-
verse Phase Protein Array (RPPA) analysis at George Washington University. For
quality control purposes, standard curves were printed on each array along with
the samples. To quantify the amount of total protein in each sample, selected
arrays were stained with Sypro Ruby staining solution (Molecular Probes, Eu-
gene, OR) pursuant to manufacturer recommendation. Before proceeding with
immunostaining, arrays were first incubated in Reblot Stripping solution (Chemi-
con, Temecula, CA) for 15 minutes, washed twice with PBS (Life Technologies,
Carlsbad, CA) and incubated in I-Block (Tropix, Bedord, MA) for one hour. Us-
ing an automatic system (Dako Cytomation, Carpinteria, CA), arrays were then
incubated with commercially available 3% hydrogen peroxidase solution, avidin-
biotin blocking system, and protein block (Dako Cytomation, Carpinteria, CA).
The expression/activation level of a panel of FDA-approved and/or under inves-
tigation drug targets and their downstream effectors was measured using a single
primary antibody targeting the protein and phosphorylation site of interest. Each
61
B.
C. D.
E. F.F.
D.
Figure 4.1: (A) Experimental design with melanoma cell lines processed with
HTS, whole genome microarray genechip, and RPPA. We performed simulations
under the HTS under the null model — no influence from GEX (B) and under
the alternative model for left asymptote differences (C), right asymptote differ-
ences (D), X-Mid differences (E), Scale differences (F), and a combination of the
parameters.
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antibody used on the array was previously validated using western blot to confirm
its specificity. A commercially available tyramide-based avidin/biotin amplifica-
tion system (CSA; Dako Cytomation, Carpinteria, CA) and fluorescent detection
(LI-COR Biosciences, Lincoln, NE) were used to quantify the amount of protein
present in each sample. Antibody stained slides were scanned using the Tecan laser
scanner (Tecan PowerScanner Tecan group Ltd., Mnnedorf, Switzerland). Images
were analyzed with MicroVigene 5.1.0.0 (Vigenetech, Carlisle, MA) as previously
described [Kaushik et al., 2014]. Because the output of the RPPA platform is
quantitative, the intensity values obtained from the analysis were reported on a
continuous variable.
4.3.5 CCLE Data Set
To provide another comparison and evaluation of the performance of dif-
ferent analysis methods, we downloaded and processed raw CEL files from the
CCLE. We obtained gene expression profiles and genome-wide mutation calls for
melanoma cell lines from the CCLE web portal.
4.3.6 Traditional IC50 DRC Analysis
For each of the 40 cell lines 9-point dose response data generated for each
of 120 drugs from the melanoma drug screen, we fit DRCs using a traditional
four parameter sigmoidal curve. The parameters governing these curves were: left
asymptote of the curve, right asymptote of the curve, midpoint of the curve (re-
ferred to as the “x-mid” value), and a scale parameter [Commo and Bot, 2015] .
All analyses, including those involving the proposed NLME models and simulation
studies described below were performed on the San Diego Supercomputer Cen-
ter (TSCC). To fit DRCs to each cell of the melanoma cell lines 9-concentration
DRC data, we used the nplr [Commo and Bot, 2015] package in R. We used a
similar DRC analyses for the CCLE data and simulated data described below.
To determine whether the IC50 values were significantly associated with the gene
expression, we used Pearson correlation tests with the paired gene expression and
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estimated IC50 values across the cell lines.
4.3.7 NLME-Based Analyses
As noted, we considered two different NLME-based models and tests for the
DRC data, each assuming the same four parameter sigmoidal curve as in the tra-
ditional IC50 analyses discussed in the previous section. For the first NLME-based
model, which we will refer to as the “IC50 NLME” model, we fit four parameter
sigmoidal curves to all the cell lines simultaneously allowing for variation in IC50
values across the cell lines. We leveraged the lme4 [Bates et al., 2015] package in
R with fixed effects for each of the four parameters in the sigmoidal curve and an
additional random effect for the “x-mid” (i.e., an estimate of the IC50) parameter
while using the cell line as a grouping factor to do so. Note that the IC50 NLME
analysis model produces IC50 values for each cell line that can be used in Pear-
son correlation tests to determine their association with other factors collected on
those cell lines, such as gene expression levels, but just estimated simultaneously
with the other cell lines.
For the second test, which we will refer to as the “Omnibus LR NLME”
model and test, we fit four parameter sigmoidal curves to stratified subsets of the
cell lines based on grouping factors, such as the cell lines expressing a gene above
and below the median gene expression value (real or simulated, depending on the
data set) or cell lines with and without a mutation. The likelihoods obtained from
each groups curve fits were then used to calculate a log-likelihood ratio statistic
comparing the DRCs between the two groups as:
LLR = −2 ∗ LLall + 2 ∗ (LLGene+ + LLGene−)
Note that since the Omnibus LR NLME test does not focus on a single
parameter, like the x-mid or IC50 value, it can in theory identify differences between
DRCs obtained from two (or more) groups that could involve the left or right
asymptote, the scale parameter, the x-mid parameter or any combination of these.
To determine the significance of the observed LLR statistic, 100 permutations were
performed for, e.g., the over and under expressed status for each cell line. For each
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permuted sample, we calculated LLRs and for each drug i and each permutation
j, we calculated Cij as:
Cij =
1, if LLRij > LLRi0, otherwise
Then, based on these permutations, for n total permutations, the p-value
for the observed stratification was:
pi =
1 +
∑n
j=1Cij
n+ 1
To save computational resources, when association test p-values were going
to exceed 0.05 based on the number of permutations we set (i.e., they were not
significant and could not achieve significance given the number of permutations),
we stopped the permutations for that setting and proceeded to the next test set-
ting. Additionally, we employed adaptive permutations [Che et al., 2014]; i.e., for
the associations that were significant at a 0.05 p-value, we increased the number
of permutations to meet multiple hypothesis testing criterion (e.g., we increased
permutations to 10,000 when testing for associations between 23 genes and 15 drug
tests).
We explored the utility of the proposed Omnibus LR NLME tests relative
to the traditional tests in a number of scenarios with the melanoma cell lines.
We computed statistics and p-values using the RPPA values stratifying the call
lines at the median intensity value. We also ran tests on all BRAF associated
genes for which we had gene expression data and the top five most significant
phosphoproteins using Pearson correlation tests for the IC50 NLME and traditional
IC50 test. As a check on the robustness of the analyses, we also assessed significance
on five random analytes for each drug. Bonferroni corrections were used to account
for multiple comparisons given the number of genes, proteins and mutations we
tested for association with drug responses across the cell lines. For the analyses
involving the CCLE data set, we compared BRAF mutant and wild type cell lines,
and compared the results against analyses using the IC50 values provided the
Broad Institute for the CCLE data set [Barretina et al., 2012].
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4.3.8 Simulation Based Tests
We simulated High Throughput Screen (HTS) nine-point Dose Response
Curves (DRCs) data assuming a four parameter sigmoidal model. We note that
each simulation required heavy computational resources (30-120+ hours and 8GB
of RAM per simulated parameter set). We assumed that the standard deviation of
the response for each concentration followed that of the observed drugs’ standard
deviations calculated from the actual melanoma cell line data. We simulated null
models in which there was no assumed relationship between a hypothetical factor
and drug response.c In addition, we simulated cell line DRCs assuming sample
sizes of 34, 50, and 100 in triplicate with a left asymptote of 100, right asymp-
tote of 10, scale of -0.5, and x-mid values following a normal distribution with
mean -0.5 and standard deviation of 0.3 (i.e., ˜N(-0.5, 0.3)) (Figure 4.1B). These
values were determined based on averages from analyses involving all the actual
melanoma samples. We then considered simulations in which half of the cell lines
were randomly assigned as over-expressing a gene with a distribution of N(8,1)
and the other half were assigned as expressing that gene to a lesser degree with a
distribution of N(3,1). Based on these simulated parameters and standard devia-
tion at each concentration, DRCS were simulated for each cell line. For each set
of parameters, 100 simulations were performed and subsequent association tests
were applied as follows: t-test of over-expressers vs. under-expressers with tra-
ditionally called IC50, t-test of over-expressers vs. under-expressers with NLME
model-derived IC50 values, and the Omnibus LR test with the NLME-fitted DRCs.
Keep in mind that differences in the test results between the IC50 values from the
traditional analysis and the IC50 NLME called IC50 values reflect the influence of
analyzing all the cell lines together rather than individually.
To evaluate the power of the association tests by exploring the impact of
changes in DRCs not associated with IC50 values, we simulated dose response
curves under different alternative models. In these simulations, under-expressed
genes were simulated with different sigmoidal curve parameters described in Figure
4.1C-E. Note that in some settings, we averaged the power of the simulations in
which one parameter was fixed but the others were allowed to vary to determine
66
how easily the three tests could detect differences in DRCs between two groups
that were not exclusively due to differences in IC50 values. To create realistic sim-
ulations, we explored various combinations (153 of the possible 192 combinations,
approximately 80%) of the parameters and performed 100 simulations for each set
of parameters.
4.4 Results
4.4.1 Simulation Based Tests
As noted, we simulated DRCs assuming triplicate cell line evaluations (to
mimic are actual data) for sample sizes of 34, 50, and 100 triplicate cell lines.
Based on the results of the analyses of this simulated data using each method
(i.e., traditional tests using individual cell line-based IC50 values, the IC50 NLME
test and Omnibus LR NLME tests) we calculated the false positive rate or type I
error rate (i.e., using the null model simulation settings) and the false negative rate,
power or type II error rate (using the alternative model simulation settings). Power
analysis revealed that 100 simulations for these analyses would suffice (Figure 4.6).
For the type I error rate, we found that each of the three association tests produced
results close to the expected value of 5% false positives, regardless of the number of
cell line samples. However, the simulation results for the Omnibus LR NLME tests
suggested it performed better in nearly every scenario (with the exception of the
largest right asymptote changes, where the IC50 NLME association tests performed
better (Table 4.1). We note that for Table 1, the three tests can be seem as not
being equally sensitive to differences in DRCs that exhibit differences in parameters
beyond the IC50, as we fixed one of the parameters and averaged the estimates of
the power estimates when the other parameters were allowed to vary. This was
to be expected, since the traditional IC50 test that estimates IC50 values for each
cell line independently and then explores the relationship between those estimated
IC50 values and some other factor on those cell lines and essentially ignores other
properties about the cell lines. The NMLE IC50 test, although focusing on the
IC50 values, is influenced by the other DRC parameter differences between the
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Table 4.1: The Mean and SD of power observed when a single parameter is fixed
between two groups and all other parameters are varied in one of the groups (see
Methods section).
Fixed Parameter Varied Parameters Trad IC50 NLME IC50 LLR
Left Asym = 100 Right Asym, X-Mid, Scale 0.12 +/- 0.11 0.73 +/- 0.35 0.77 +/- 0.24
Left Asym = 90 Right Asym, X-Mid, Scale 0.13 +/- 0.10 0.61 +/- 0.38 0.73 +/- 0.24
Left Asym = 80 Right Asym, X-Mid, Scale 0.11 +/- 0.08 0.42 +/- 0.32 0.85 +/- 0.07
Left Asym = 70 Right Asym, X-Mid, Scale 0.09 +/- 0.08 0.49 +/- 0.33 0.83 +/- 0.09
Right Asym = 10 Left Asym, X-Mid, Scale 0.12 +/- 0.10 0.41 +/- 0.33 0.69 +/- 0.29
Right Asym = 20 Left Asym, X-Mid, Scale 0.12 +/- 0.10 0.46 +/- 0.33 0.78 +/- 0.14
Right Asym = 30 Left Asym, X-Mid, Scale 0.12 +/- 0.10 0.61 +/- 0.36 0.87 +/- 0.08
Right Asym = 40 Left Asym, X-Mid, Scale 0.11 +/- 0.08 0.93 +/- 0.13 0.86 +/- 0.08
X-Mid = -0.5 Right Asym, Left Asym, Scale 0.05 +/- 0.02 0.48 +/- 0.34 0.79 +/- 0.21
X-Mid = -0.4 Right Asym, Left Asym, Scale 0.05 +/- 0.02 0.47 +/- 0.35 0.76 +/- 0.23
X-Mid = -0.25 Right Asym, Left Asym, Scale 0.12 +/- 0.03 0.59 +/- 0.37 0.80 +/- 0.20
X-Mid = 0 Right Asym, Left Asym, Scale 0.28 +/- 0.05 0.79 +/- 0.32 0.82 +/- 0.10
Scale = -0.5 Right Asym, Left Asym, X-Mid 0.12 +/- 0.09 0.62 +/- 0.36 0.74 +/- 0.20
Scale = -0.4 Right Asym, Left Asym, X-Mid 0.12 +/- 0.11 0.58 +/- 0.35 0.76 +/- 0.24
Scale = -0.2 Right Asym, Left Asym, X-Mid 0.12 +/- 0.09 0.53 +/- 0.38 0.88 +/- 0.07
two groups since it estimates parameters for the groups using all the data and can
therefore detect differences in DRCs beyond differences in IC50 values.
When exploring specific settings, the association tests using traditionally
derived IC50 values (i.e., that are estimated independently from each cell line) ex-
hibited a type 1 error rate consistent with the null model (e.g., 0.05) in cases where
differences in DRCs were simulated that involved changes in left asymptote, right
asymptote, and scale (Table 4.2). Note that in Table two, the values highlighted
in red denote differences in assumed parameter values between the two groups.
Moreover, we do find that the traditional IC50 association tests performed signifi-
cantly poorer when the x-mid parameters were fixed (i.e., x-mid were the same in
both groups; first two rows of Table 4.2). This was expected since, as noted, the
IC50 association tests are designed to detect differences between changes in the
X-Mid (i.e., estimated IC50 values) parameters (Table 4.2). However, in both the
IC50 NLME test and Omnibus LR NLME tests, there is a marked improvement in
the power to detect the DRC differences (Table 4.2). Although there was a slight
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improvement in the simulated settings where differences in x-mid values were as-
sumed, interestingly the traditionally-derived IC50 association tests (i.e., where
each cell lines DRC x-mid or estimated IC50 value is estimated independently)
exhibited much less power.
We compared the statistical power of each of the tests using paired two-
sample t-tests and found that the traditionally derived IC50 association tests per-
formed worse than the NLME (paired 2-sample t-tests statistics = 11, pval <
2.2e-16) and LLR tests (paired 2-sample t-tests statistics = 27, pval < 2.2e-16).
Even upon increasing the number of sample sizes to 50 and 100 cell lines, the
Omnibus LR NLME tests had greater statistical power than IC50 NLME and tra-
ditional IC50-based association tests (Table 4.5, Figure 4.7). As noted, when the
x-mid parameter is held constant, i.e. the x-mid is the same in both group, then
the traditional IC50 association tests are close to the assumed Type I error rate, as
expected (Table 4.2). Ultimately, we observed that the Omnibus LR NLME tests
exhibited the greatest power to detect differences in the dose response curves,
without sacrificing type I errors or generating many false positive associations.
However, it also proved to be the most computationally demanding method for
association tests.
4.4.2 Comparing the Different Methods on the Gene Ex-
pression Data
To assess the properties of association tests based on traditionally estimated
IC50 (x-mid) values against the IC50 NLME test, we performed association tests
using drugs with NLME curve fits to cell lines that had at least one cell line
with cell viability less than 20%. Since a subset of the drugs in our study target
the BRAF-mediated pathway, we suspect that differential drug response may be
observed based on the BRAF associated genes’ expression patterns. However,
based on analyses of these 15 drugs, no BRAF associated genes were significantly
associated when using IC50 NLME test, and only four significant associations were
found with traditional IC50 calls: HSPA9 (adjusted p-value < 0.027) and KSR1
(adjusted p-value < 0.028) with Vorinostat; RAF1 (adjusted p-value < 0.007) and
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Table 4.2: Simulation-based power to detect differences between DRCs between
two groups assuming different features about the groups DRCs.
Group 1 Parameters Group 2 Parameters Power
Simulated CLs Left Right XMid Scale Simulated CLs Left Right XMid Scale Trad IC50 NLME IC50 LLR Test
50 100 10 -0.5 -0.5 50 100 10 -0.5 -0.5 0.06 0.11 0.01
100 100 10 -0.5 -0.5 100 100 10 -0.5 -0.5 0.04 0.06 0.04
50 100 10 -0.5 -0.5 50 100 10 -0.4 -0.5 0.07 0.18 0.02
50 100 10 -0.5 -0.5 50 100 10 -0.25 -0.5 0.16 0.66 0.24
50 100 10 -0.5 -0.5 50 100 10 0 -0.5 0.39 1.00 0.90
50 100 10 -0.5 -0.5 50 100 10 -0.5 -0.4 0.00 0.06 0.49
50 100 10 -0.5 -0.5 50 100 10 -0.5 -0.2 0.06 0.08 0.86
50 100 10 -0.5 -0.5 50 100 20 -0.5 -0.5 0.02 0.34 0.81
50 100 10 -0.5 -0.5 50 100 30 -0.5 -0.5 0.07 0.90 0.99
50 100 10 -0.5 -0.5 50 100 40 -0.5 -0.5 0.04 1.00 0.88
50 100 10 -0.5 -0.5 50 90 10 -0.5 -0.5 0.05 0.34 0.69
50 100 10 -0.5 -0.5 50 80 10 -0.5 -0.5 0.04 0.86 0.98
50 100 10 -0.5 -0.5 50 70 10 -0.5 -0.5 0.02 1.00 0.98
100 100 10 -0.5 -0.5 100 100 10 -0.4 -0.5 0.09 0.20 0.07
100 100 10 -0.5 -0.5 100 100 10 -0.25 -0.5 0.29 0.96 0.63
100 100 10 -0.5 -0.5 100 100 10 -0.5 -0.4 0.05 0.07 0.84
100 100 10 -0.5 -0.5 100 100 40 -0.5 -0.5 0.09 1.00 1.00
100 100 10 -0.5 -0.5 100 90 10 -0.5 -0.5 0.05 0.63 0.99
100 100 10 -0.5 -0.5 100 80 10 -0.5 -0.5 0.09 1.00 1.00
100 100 10 -0.5 -0.5 100 70 10 -0.5 -0.5 0.04 1.00 1.00
Key: Values shown present the number of cell lines (CLs), the left asymptote,
right asymptote, X-Mid, and Scale for each simulation. Power results were
calculated using tests based on traditionally estimated IC50 values, NLME
estimated IC50, and the Omnibus LLR tests. In each simulation, one group was
held constant with the following parameters. The values highlighted in red
denote differences in the assumed parameter values for the two groups. Note that
the first two rows are simulations under the null hypothesis (i.e., no difference in
parameter settings between the two groups).
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HSPA9 (adjusted p-value < 0.03) with Crizotinib. Scatterplots comparing these
correlations highlighted the differences in the nature of the associations between
the traditional IC50 and IC50 NLME-based methods (Figure 4.2A). Although there
was a general positive correlation, we observed a great deal of variation observed
when using the two different curve fit methods.
4.4.3 Comparing the Different Methods on the RPPA Data
Similar to the gene expression analysis, we compared the associations be-
tween proteins and drug responses defined by the traditional IC50 and the IC50
NLME-based tests across the cell lines (Table 4.5). As with the results observed
for the gene expression correlation analysis, we found that using different methods
for obtaining the IC50 parameters yielded different sets of genes associated with
drug response (Figure 4.2B-C). Across all drugs, we found only significant RPPA
associations when using IC50 NLME tests (Caspase 6 (cleaved Asp162) with the
drug Thioguanine Bonferroni adjusted p-value = 0.026). However, using tradi-
tional methods, we found seven significant associations in the first RPPA set and
eleven significant associations in the second RPPA set.
4.4.4 Assessing the Omnibus LR NLME Test
To test whether gene expression was associated with overall drug response
profiles and not just IC50 values, we stratified cell lines based on their gene expres-
sion levels for those genes in the BRAF pathway. For each gene, the samples were
either labeled as over-expressed or under-expressed based on the median intensity
level across all cell lines. LLRs were calculated for each gene and drug combina-
tion, and permutation-based tests were performed to assess statistical significance
(Figure 4.3A-B, Table 4.5). Notably, only a small fraction of the differentially
expressed genes were significantly associated with drug response. This result is
particularly noticeable in the heatmaps representing the differential effects (Fig-
ure 4.3A). Specifically, the more significant gene associations appear to be limited
to Daunaribicin, Doxorubicin, Vorinostat, and Cladribine (Figure 4.3A). To ac-
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Figure 4.2: Differences observed between using traditionally called IC50, NLME
called IC50, and LLR tests. (A) −log10p-values for associations between probe
set expressions and traditionally called IC50 or NLME called IC50. (B) −log10p-
values for associations between RPPA set 1 expression and traditionally called
IC50 or NLME called IC50. (C) −log10p-values for associations between RPPA
set 2 expression and traditionally called IC50 or NLME called IC50. (D) Dose
response curves fit individually for Cladribine. (E) Dose response curves leveraging
information across cell lines, which balances inter- and intra- cell line variability.
72
count for multiple hypothesis testing, we increased the permutations to a total of
9,999 for those with potentially significant p-values based on the initial Omnibus
LR NLME tests. We found a single gene association significant beyond multiple
hypothesis testing corrections (KIDDINS220 with Daunorubicin, p-value < 1e-4).
However, there were several other cases that yielded strong (but not beyond mul-
tiple hypothesis testing correction thresholds) association between gene expression
and drug response (Figure 4.3C).
4.4.5 Assessing the Consistency Between the RPPA and
Gene Expression Analyses
To investigate potential relationships between gene and protein expression,
we used un-adjusted NLME association p-values associated with each drug to iden-
tify proteins encoded by specific genes that were also seemingly associated with
drug response. Using this strategy, many genes exhibited gene expression lev-
els and their corresponding protein levels that were significantly associated with
drug response. After consistencies between the GEX and RPPA analyses were
found, we mined molecule-interaction databases to identify a biological basis for
the observed results. Admittedly, this was not an exhaustive search, but we found
several compelling cases to support efforts to combine insights from transcrip-
tomics and proteomics using the NLME models and LLR tests. For Daunoru-
bicin, we found the increased expression of phosphorylated MSK1 (anti-MSK1:
phosphor S360) conferred resistance, whereas the increased expression of phos-
phorylated PKC (Phospho-PKCα/βII: Thr638) and PKCα (anti-PKC: Ser657)
were associated with sensitivity to the drug (Figure 4.3C, Figures 4.8-4.9). In an-
other compelling example, over-expression of MAPK3 was a significant predictor
of response to Cladibrine. Furthermore, we observed that cell lines responsive to
Cladibrine also had lower expression in the protein pBAD S112, which is known
to be associated with the BCL pathway (Figures 4.10-4.11). Similarly, we found
that over-expression of the KSR1 gene was associated with response to the drug
LDK378 (Figure 4.12). KSR1 and FKHR have many physical interactions or are
co-expressed with many of the same genes (Figure 4.13).
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Figure 4.3: LLR tests for assessing significant gene expression association in
BRAF-related genes. (A) Heatmap of p-values across 15 drugs. (B) Dose response
curves fit within KIDINS220 over-expression (Green) and under-expression (Grey).
(C) Dose response curves fit in over- and under-expressed phosphoproteins with
strong associations.
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4.4.6 Analysis of the CCLE data with NLME-Based Mod-
els
To explore whether or not the manner in which the IC50 values were esti-
mated had an impact on the identification of relationships between drug response
and gene expression values, we fit NLME models across all the CCLE cell lines
for each available drug and compared the results of these NLME-assigned x-mid
(IC50) values against the available IC50 values computed by the CCLE research
team (Figure 4.14). Although we observed a general concordance between the two
IC50 estimates, we found that the methods yielded different values across the cell
lines. Additionally, fitting NLME curves across cancer types allowed us to assess
each drug’s response profile within cancer types. For example, we identified AZD-
6244 as a candidate drug in melanoma since it had a more significant NLME curve
fit relative to other cancer types.
4.4.7 Including Mutation Status as Random Effect in CCLE
Data
Fitting NLME curves within groups of cell lines stratified by mutation sta-
tus could provide more accurate IC50 assessments if mutation status impacts drug
responsiveness. Based on our NLME curve fits to the CCLE cell lines, we found
that, overall, melanoma cell lines were more sensitive to the drug AZD-6244 than
other cancer types. To assess the impact of incorporating mutation status into
NLME curve fits, we stratified the cell lines into BRAF mutant verse BRAF wild
type cell lines. Although the mutation status did not impact curve fits for most
CCLE drugs, we found that the BRAF wild type samples were much more resistant
to AZD-6244 (Figure 4.4A). NRAS mutations were also associated with response
to AZD-6244. However, melanoma cell lines with NRAS mutations appeared to
have a greater sensitivity than those with BRAF mutations (Figure 4.4A).
To assess concordance between our UACC melanoma cell lines and the
CCLE melanoma cell lines, we compared NLME curve fits by subdividing the cell
lines by BRAF and NRAS mutation status in both data sets. We found cases where
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mutation status had an opposite impact on curve fits between the two data sets –
though this is likely due to differences in cell lines used. For example, for the drug
Topotecan, we found that NRAS mutations led to greater sensitivity and BRAF
mutations led to greater resistance in the CCLE cell lines (Figure 4.4B) compared
to the UACC cell lines. However, in our UACC cell lines, both NRAS and BRAF
mutations led to greater sensitivity to the Topotecan (Figure 4.4C). This suggests
that while the mutation status could help improve NLME curve fits, careful data
analyses should be considered. In this particular case, we suggest incorporating
the NRAS mutation status, but omitting the BRAF mutation status, in fitting
NLME curves for Topotecan in melanoma cell lines.
4.5 Discussion
HTS studies using tumor cells lines can illuminate the relationship between
drug responsiveness and various factors collected on those cell lines (like gene ex-
pression levels, mutation status, etc.). Such relationships can be exploited clinically
to “personalize” cancer treatments. However, there have been recent concerns sur-
rounding the reliability HTS studies using tumor cell lines [Garraway et al., 2013]
[Shrager and Tenenbaum, 2014] [Barretina et al., 2012] [Yang et al., 2013] [Gillet
et al., 2013] [Wang et al., 2016]. One question about such screens concerns the
analysis methods used to draw inferences about the relationships between cell line
drug responses and characteristics of the cell lines. Traditional methods of mea-
suring drug response in HTS consider cell lines in isolation and do not leverage
information across all available cell lines used in the screen. To overcome this
limitation, we considered NLME models to analyze multiple dose response curves
simultaneously to account for the variability across the cell lines. Thus, instead of
using single parameters extracted from individual dose response curves to assess
associations, we use overall curve fits to a group of cell lines that accommodates
association tests. The two tests we introduced, the IC50 NLME-based test and
the Omnibus LR NLME test, each have advantages and disadvantages. The clear
advantage of the Omnibus LR test is that it does not consider a single parame-
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Figure 4.4: LLR tests for assessing significant stratification of cell lines with or
without mutations in CCLE and SU2C cell lines. (A) Assessment of AZD6244 in
CCLE across all cell lines (Black), melanoma BRAF+ (Solid Blue), and melanoma
BRAF- (Dotted Blue). (B) Same as A, but with Topotecan. (C) Assessment of
Topotecan in SU2C across all cell lines (Black), BRAF+ (Solid Blue), BRAF-
(Dotted Blue), NRAS+ (Solid Red), and NRAS- (Dotted Red)
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ter in the analysis of DRCs, but rather assumes the overall shapes of the curves
between two groups (we note that it would be easy to generalize the test to more
than two groups) defined on an assumed associated cell line characteristic like gene
expression level, are different.
We pursued simulation studies to assess false positive rates and the statis-
tical power of NLME methods relative to traditional methods. Our simulations
showed that NLME-based tests, in particular the proposed Omnibus LR NLME
test, are more powerful than standard tests. However, these simulations are very
computationally expensive, especially for the Omnibus LR NLME test, and as a
result we suggest that if adequate computational resources are not available, then
the use of more efficient tests that still leverage NLME models, such as the IC50
NLME test, can be used.
We applied the NLME-based tests in order to see if they could identify
differential gene expression and protein level associations with drug response in
more powerful and compelling ways than traditional individual DRC IC50based
analytical methods. We found evidence for many associations that could not be
attributed to chance. Upon mining gene and protein interaction databases, we
observed that many of the associations we observed several were consistent with
previously published data. For example, we found that the differential expression
of the MAPK3 gene stratified melanoma cell lines into Cladribine responders and
non-responders, which is consistent with what is known about the mechanism of
action of Cladribine. Based on this finding, and in conjunction with the interroga-
tion of the DGIdb database, we found that kinase inhibitors 5-Iodotubercidin and
Purvalanol are likely drug candidates for these cell lines.
Our analyses and observations suggest that NLME-based models for fitting
and analyzing DRCs could complement current HTS strategies and infrastructure.
However, these NLME methods require, as noted, a fairly heavy computational
burden, especially if one wants to rely on permutation-based methods for obtaining
p-values for the Omnibus LR NLME test, and may not be optimal in every context;
e.g., when one wants to search the entire HTS space for gene by drug interactions
which could be huge. In an ideal world, every association among genes, proteins,
78
and drugs could be explored. Given the computational burden, we opted for a
biologically-guided search (e.g., searching for BRAF-related genetic associations in
melanoma) that ultimately led to compelling associations between genes and drug
responses. The use of NLME-based analysis approaches that we document here
can be extended to test associations between other important factors (e.g., Copy
Number Variations, DNA methylation status, Single Nucleotide Polymorphisms,
etc.) and drug response. Ultimately, we believe that the NLME approach to
analysis of HTS dose-response data is flexible, robust and powerful enough to be
used routinely.
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4.7 Supplemental Figures and Tables
Figure 4.5: GeneMANIA BRAF-related network with K = 20. Key: Pink =
Physical interactions; Purple = Co-expression; Orange = Predicted; Light Blue
= Pathway; Dark Blue = Co-localization; Green = Genetic interactions; Yellow
= Shared protein domain; and size of circle is proportional to the number of
connections.
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Figure 4.6: Power analysis for simulations. Based on the observed correlations
from initial parameter simulations (cor > .5), 100 simulations should suffice.
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Figure 4.7: Simulation-based power does improve with increased sample size in
both the NLME called IC50 associations and in the LLR associations. Statistical
power in traditionally called IC50 associations tests yielded the worst results.
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Figure 4.8: Application of LLR tests to identify concordant RPPA (Phospho-
PKCα/βII (Thr638)) and Gene expression (KIDINS220) that stratify Dauanoru-
bicin dose response curves.
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Figure 4.9: Application of LLR tests to identify concordant RPPA (anti-PKCα
(Ser657)) and Gene expression (KIDINS220) that stratify Dauanorubicin dose re-
sponse curves.
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Figure 4.10: Application of LLR tests to identify concordant RPPA (pBAD) and
Gene expression (MAPK3) that stratify Cladribine dose response curves.
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Figure 4.11: GeneMANIA pathway analysis using BRAF and BCL2 showing the
network connection of MAPK3 and pBAD.
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Figure 4.12: Application of LLR tests to identify concordant RPPA (FKHR) and
Gene expression (KSR1) that stratify LDK378 dose response curves.
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Figure 4.13: GeneMANIA pathway analysis using BRAF and BCL2 showing the
network connection of FOXO1 (FKHR) and KSR1.
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Figure 4.14: Comparing the effects of estimating IC50 values (uM) with NLME
models and those of traditional methods. Although overall correlation is observed,
there are some clear variations.
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Table 4.3: Table of cell lines available in the SU2C study. HTS represents
availability of high throughput drug screen, GEX represents availability of whole
genome microarray genechips, and RPPA sets 1 and 2 represent the availability of
Reverse Phase Protein Arrays.
SU2C Cell Lines Nine Point HTS GEX RPPA Set 1 RPPA Set 2
A375 Y N N Y
HEMnLP Y Y N N
MeWo Y Y N Y
SKMEL113 Y N N Y
SKMEL119 Y N N Y
SKMEL2 Y Y N Y
SKMEL21 Y N N Y
SKMEL217 Y N N Y
UACC0091 Y Y Y Y
UACC0257 Y Y Y Y
UACC0502 Y Y Y Y
UACC0558 Y Y Y Y
UACC0612 Y Y Y Y
UACC0647 Y Y Y Y
UACC0903 Y Y Y Y
UACC0952 Y Y Y Y
UACC1093 Y Y N Y
UACC1097 Y Y Y Y
UACC1113 Y Y Y Y
UACC1118 Y Y Y Y
UACC1120 Y Y Y Y
UACC1237 Y Y Y Y
UACC1265 N Y N N
UACC1308 Y Y Y Y
UACC1469 Y Y Y Y
UACC1649 Y N N Y
UACC1729 Y Y Y Y
UACC1940 Y Y Y Y
UACC2331 Y Y Y Y
UACC2427 Y Y Y Y
UACC2496 Y Y Y Y
UACC2610 Y Y Y Y
UACC2641 Y Y Y Y
UACC2851 Y Y Y Y
UACC2972 Y Y Y Y
UACC2994 Y N N Y
UACC3074 Y Y Y Y
UACC3093 Y Y Y Y
UACC3291 Y Y Y Y
UACC3312 Y Y Y Y
UACC3337 Y Y Y Y
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Table 4.4: Total number of significant associations based on Traditionally called
IC50 and NLME called IC50 vales.
Azacitidine Doxorubicin Cladribine Vorinostat Crizotinib Thioguanine Daunorubicin OSI027
RPPA Set 1 Trad Sig 0 0 1 0 0 3 3 1
RPPA Set 1 NLME Sig 0 0 0 0 0 1 0 0
RPPA Set 2 Trad Sig 1 1 0 2 1 4 1 1
RPPA Set 2 NLME Sig NA 0 0 0 0 NA 0 0
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Table 4.5: P-values for LLR tests stratifying gene expression at the median value.
Tests were performed across 15 drugs and BRAF-related genes.
Gene Name Azacitidine Doxorubicin Cladribine Vorinostat Clofarabine Etoposide Thioguanine
RAP2A NA 1.000 0.010 0.250 0.866 1.000 1.000
KIDINS220 NA 0.010 0.667 1.000 0.904 1.000 0.944
RAF1 NA 0.091 0.667 0.667 1.000 0.286 0.500
HSP90AB1 NA 0.500 1.000 0.500 0.500 1.000 1.000
HSPA9 NA 0.167 1.000 1.000 0.500 0.941 1.000
YWHAQ NA 0.200 0.667 1.000 1.000 0.667 1.000
YWHAH 1.000 0.667 0.051 1.000 0.222 1.000 NA
ARAF 1.000 0.080 0.667 1.000 1.000 0.667 1.000
MAP2K2 1.000 1.000 1.000 0.667 1.000 1.000 0.300
MAP2K1 1.000 1.000 0.111 0.010 0.400 0.500 1.000
PHKB 1.000 1.000 0.125 0.400 1.000 1.000 1.000
LIMK1 NA 1.000 0.059 0.010 0.074 0.500 NA
BRAF /// KIAA1549 NA 0.286 0.100 0.333 0.222 0.500 0.500
RIT2 NA 1.000 1.000 0.500 1.000 1.000 1.000
RIT1 NA 1.000 1.000 1.000 0.667 0.300 0.400
CDC37 NA 0.143 0.667 0.667 1.000 1.000 1.000
HSPA5 0.750 0.500 0.010 0.400 0.800 1.000 0.667
MAPK3 NA 0.286 1.000 1.000 0.667 0.667 1.000
KSR1 1.000 0.020 0.200 0.333 0.222 NA 1.000
RAP2A /// RAP2B 0.667 0.154 1.000 1.000 0.111 0.852 0.500
RAP2C 1.000 0.333 0.667 0.667 0.667 NA 1.000
RNF149 NA 1.000 0.250 0.333 1.000 1.000 1.000
BRAF NA 0.667 0.667 1.000 1.000 NA 1.000
Gene Name Irinotecan Mitoxantrone Mitomycin Daunorubicin OSI MLN4924 LDK378
RAP2A 0.125 0.667 0.600 0.500 0.125 0.667 0.222
KIDINS220 1.000 1.000 1.000 0.010 1.000 0.667 0.200
RAF1 0.111 0.667 0.500 0.010 1.000 1.000 1.000
HSP90AB1 0.667 1.000 1.000 0.067 1.000 0.667 0.667
HSPA9 0.222 NA NA 0.059 0.400 1.000 0.051
YWHAQ 1.000 1.000 0.667 1.000 1.000 0.667 1.000
YWHAH 1.000 NA 1.000 1.000 0.400 1.000 0.500
ARAF 1.000 NA NA 0.200 1.000 0.400 1.000
MAP2K2 1.000 1.000 NA 1.000 0.333 1.000 1.000
MAP2K1 0.182 1.000 1.000 0.111 1.000 0.667 1.000
PHKB 0.667 1.000 1.000 1.000 1.000 1.000 1.000
LIMK1 0.667 1.000 1.000 0.500 0.167 NA 1.000
BRAF /// KIAA1549 1.000 0.286 1.000 1.000 1.000 0.667 1.000
RIT2 1.000 0.500 1.000 1.000 1.000 0.333 0.182
RIT1 0.286 1.000 0.400 0.333 0.200 0.500 0.333
CDC37 1.000 NA 1.000 0.667 1.000 1.000 0.667
HSPA5 0.667 0.800 1.000 1.000 1.000 1.000 0.182
MAPK3 0.200 NA 0.667 0.167 0.500 1.000 1.000
KSR1 0.400 NA 1.000 0.010 1.000 NA 0.400
RAP2A /// RAP2B 0.154 1.000 0.267 0.667 0.010 0.667 0.020
RAP2C 0.667 0.167 0.172 0.167 0.667 1.000 1.000
RNF149 1.000 1.000 1.000 0.125 1.000 1.000 0.500
BRAF 1.000 NA 0.333 0.333 0.667 0.667 1.000
Chapter 5
Network Rewiring in Cancer:
Applications to Melanoma Cell
Lines and The Cancer Genome
Atlas Melanoma Patients
5.1 Abstract
Genes do not work in isolation, but rather as part of networks that have
many feedback and redundancy mechanisms. Studying the properties of genetic
networks and how individual genes contribute to the overall functioning of a net-
work can provide insight into genetically-mediated disease processes. This is par-
ticularly true in the context of cancer, where there are known differences between
cancerous and non-cancerous tissues with respect to how genes function together
as networks. Most analytical techniques for identifying genes contributing to dys-
functional genetic networks assume a network topology (i.e., connections between
genes) that is based on how the network functions in normal or non-diseased states.
This is problematic since perturbations in genes often have “ripple” effects that
lead to the rewiring of relevant networks and impact relationships among other
genes. We apply a suite of analysis methodologies to assess the degree of tran-
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scriptional network rewiring observed in different sets of melanoma cell lines using
whole genome gene expression microarray profiles, skin fibroblasts obtained from
Gene Expression Omnibus (GEO), and cancer cell lines from the Cancer Cell Line
Encyclopedia (CCLE). We also assess evidence for network rewiring attributable
to mutations in melanoma patient tumor samples using RNA-sequence data avail-
able from The Cancer Genome Atlas (TCGA). We make a distinction between
“unsupervised” and “supervised” network-based methods and contrast their use
in the identification of consistent differences in networks between subsets of cell
lines and tumor samples. Ultimately, we argue that our results have important
implications for understanding the molecular pathology of melanoma as well as
the choice of treatments to combat that pathology.
5.2 Introduction
Many studies leveraging genomic assays explore associations between genes
and diseases. If any associations are found then strategies to make broader claims
about genetically-mediated processes, networks, and pathways that mediate those
diseases are pursued; for example, by studying the expression levels or protein
function of disease-associated genes. Identifying genetically-mediated molecular
physiologic processes underlying a disease could lead to insights into how to combat
or treat the disease. One strategy for identifying molecular physiologic processes
responsible for a disease is to measure gene expression of diseased and non-diseased
tissues. Then, differentially expressed genes could be extracted to determine if
some subset of regulated genes participate in a coherent network or contribute
to particular processes. Although intuitive, there are some complications to such
analyses. For example, in making claims about whether or not the differentially
expressed genes (DEGs) all participate in a particular network, the list of DEGs
is compared to databases, such as Kyoto Encyclopedia of Genes and Genomes
[Kanehisa and Goto, 2000] (KEGG) or WikiPathways [Pico et al., 2008] [Kutmon
et al., 2016] [Kelder et al., 2012], which provide network, function, or pathways
associated with each gene. If the DEGs match lists of genes in known networks,
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then it can be inferred that those networks are likely to be contributing to the
pathogenesis of the disease [Costanzo et al., 2010] [Blomen et al., 2015].
Such strategies do not address crucial questions about the relationships
between the genes, i.e., their correlations, which might be necessary to determine
the potential effect of a drug on those genes as a network. For example, it might
be necessary to know if the inhibition of one gene in the network will lead to the
inhibition or excitation of another. In order to assess the relationships between the
genes, and whether those relationships are themselves different in the diseased or
normal state, one would need to have some basal “wiring” diagram or “topology”
associated with the network that provides insight into which genes might influence
other genes. Unfortunately, most network topologies or wiring diagrams have
been devised from studying genes in the normal (i.e., non-diseased) state [Snider
et al., 2015] [Califano, 2011] [Ideker and Krogan, 2012]. This is problematic if
the networks have become “rewired” (i.e., the topology or connections between
the genes is fundamentally different) in the disease state, since then the simple
assessment of the differences in the relationships between pairs of genes in the
normal and diseased tissues would not reveal differences at the more holistic or
network level, and the choice of which pairs of genes to assess guided by the network
topology obtained in the normal state may not point out crucial relationships
unique to the diseased state.
As an example of this problem, consider the fact that many drug target iden-
tification and modulation studies focus on how drugs impact levels of gene expres-
sion or protein in wild-type, normal, or conveniently available cell lines [St Onge
et al., 2007] . If the communication between genes is fundamentally different in
the diseased state, then extrapolating a drugs effects on genes or protein levels in
the normal state to that of the diseased state may be problematic (see Figure 5.1A
for simple hypothetical example). Another issue with the characterization of the
relationships between genes is that there may be many genes in a given network,
creating a large number of relationships to consider [Hofree et al., 2013]. This cre-
ates computational and inferential challenges. In addition, such analyses require
that one pre-specify the groups whose gene-gene relationships are to be contrasted
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(e.g., BRAF mutant positive tumors vs. BRAF wild-type tumors in melanoma).
To identify differences in network architecture within a given data set,
one could pursue a “unsupervised” or “supervised” approach. Supervised ap-
proaches such as Evaluation of Dependency DifferentialitY [Jung and Kim, 2014]
(EDDY), Gene Set Enrichment Analysis [Mootha et al., 2003] [Subramanian et al.,
2005], (GSEA), and Gene Set Co-expression Analysis [Choi and Kendziorski, 2009]
(GSCA) are limited to the settings in which the grouping of the cells or tissues
is set in advance, and hence requires prior knowledge of, e.g., disease and normal
conditions. Unsupervised methods do not require that the groups be specified a
priori, but often generate results that might be difficult to interpret or reconcile
with the results of other unsupervised methods. In addition, most available un-
supervised genetic analysis methods focus on exploring differences in the means
or mean vectors of the factors among groups (e.g., gene expression values, pro-
tein abundances, etc.) as a way of determining which factors may be contributing
to differences between them. However, if, as noted, the rewiring of the genetic
networks among the groups upsets the relationships or correlations between the
genes (i.e., not the mean differences between them), then focusing on mean gene
expression levels will not identify the group differences.
We consider the value of both supervised and unsupervised approaches
in the analysis of network data [Ideker and Krogan, 2012] [Yang et al., 2014]
[Oros Klein et al., 2016]. We assessed evidence for network rewiring in a variety of
melanoma drug screen data and The Cancer Genome Atlas [The Cancer Genome
Atlas Research Network et al., 2013] (TCGA) tumor profile data sets. We further
consider the implications such rewiring might have for making claims about cell
line responses to drugs. Specifically, we pursued supervised analyses of genetic
networks by stratifying melanoma cell lines into groups defined by BRAF and/or
KRAS mutation status and then evaluating differences in the overall network struc-
ture (i.e., relationships between genes). Using this strategy, we sought to identify
genes that appeared to have a more central role in those networks. We then per-
formed network analyses with patient samples from TCGA melanoma data. We
observed that the cell lines exhibited a greater degree of network rewiring or dif-
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Figure 5.1: (A) Figure 1: (A) Example of network rewiring that could occur.
Under ideal conditions, Gene A is co-regulated with Gene D through gene B.
When gene B is inhibited, there could be a compensatory mechanism for which
gene A communicates with gene D in this example, that is potentially gene C.
(B) Mutation status of 33 melanoma cell lines and HeMnLP processed with whole
genome microarray gene chips at the Translational Genomics Research Institute.
TCGA type calls are based on known pathogenic hotspots for BRAF and RAS
(e.g. BRAF V600 mutations), but are more open-ended for NF1. Point mutations
are provided for BRAF, RAS, and NF1. Cell lines are ordered by TCGA mutation
type, point mutation, and then cell line number.
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ferences than the patient samples and therefore leveraged unsupervised methods
to explore the variation in network behavior. These analyses allowed us to identify
potential drug targets and could shed light on how to match patient genetic profiles
to specific treatments by exploiting the Drug Gene Interaction database [Wagner
et al., 2016] (DGIdb). Ultimately, our proposed methods provide a strategy for
identifying unique network features among tumors and subsequently exploiting
those unique features for drug targeting purposes.
5.3 Materials and Methods
5.3.1 Transcriptional Profile on Cell Lines
We leveraged a number of melanoma cell lines. Including the UACC cell
lines maintained at the Translational Genomics Research Institute (TGen) in
Phoenix, AZ. All the TGen UACC cell lines were of low passage number (Fig-
ure 5.1B) and were maintained according to the manufacturer’s or collaborator’s
instructions. All cell lines were stored and evaluated in media with 10% FBS and
1% AA added. The low passage cell lines were maintained in multiple aliquots
as liquid nitrogen stocks to reduce risk of phenotypic drift. All cells were cul-
tured for less than three months before reinitiating culture from the frozen stock
and routinely inspected for identity by morphology and growth curve analysis and
validated to be mycoplasma free. All cell lines were free of contaminants.
The cell line samples were used for nucleic acid extraction, verification,
amplification, and hybridisation to Affymetrix HG-U133 plus 2.0 arrays (54,675
probesets, Affymetrix, Santa Clara, CA) using standard protocols for Affymetrix
GeneChip microarrays. Affymetrix HG-U133 Plus 2.0 microarrays were normalized
(background adjustment, interquartile normalization, and median polish) using
robust multichip averaging [Irizarry et al., 2003] in R. To assess network rewiring
that occurs within melanoma cell lines against a control group, we normalized
expression profiles across melanoma cell line and skin fibroblast samples (Table
5.8, Figure 5.7). All subsequent analyses were based on normalization only within
melanoma cell lines (Figure 5.8).
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We also obtained the SK-MEL-2 melanoma cell line from the Cancer Cell
Line Encyclopedia (CCLE), and the MeWo melanoma cell line from the Devel-
opmental Therapeutics Program’s NCI-60. In addition, we leveraged microarray
gene expression data on skin fibroblast samples (n = 29) from Gene Expression
Omnibus, (GEO) (Table 5.8). The skin fibroblast samples varied in age and eth-
nicity (Caucasian and Puerto Rican). Finally, we obtained gene expression data
from the TCGA melanoma samples from the Broad GDAC Firehose (n = 474).
Raw CEL files were downloaded from the CCLE web portal. All samples from the
CCLE, NCI-60, and GEO were performed on Affymetrix HG-U133 plus 2.0 arrays.
All microarray samples were re-normalized together to ensure minimal batch ef-
fects. Normalization of all microarray data (background adjustment, interquartile
normalization, and median polish) was completed using robust multichip averag-
ing [Irizarry et al., 2003] [Gautier et al., 2004] in R. We obtained RAF and RAS
mutation status on the CCLE cell lines from the Oncomap mutation provided in
the CCLE web portal and additional binary calls for copy number and mutation
data from the CCLE web portal.
5.3.2 MAPK Pathway Information
We took advantage of a wide variety of data analysis techniques, as de-
scribed in detail below but focused much of our analyses on sets of genes in the
MAPK pathway, which were extracted from the information in the WikiPathways
[Kutmon et al., 2016] [Kelder et al., 2012] resource. We ultimately matched MAPK
pathway genes to probe sets in the Affymetrix arrays used on for transcriptional
profiling on the cell lines. We also matched MAPK genes to those evaluated in
TCGA RNAseq dataset. For genes with multiple probe set matches, the probe set
with the maximum average intensity was used. We fit multivariate mixture models
using flexmix [Leisch, 2004] [Grn and Leisch, 2008] [Grn and Leisch, 2007], assum-
ing that there were two (BRAF+ vs BRAF-) or three (possible sub-grouping for
BRAF-) overarching different groups with gene expression values as the dependent
variables.
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5.3.3 Unsupervised Network Rewiring Analysis
In order to conduct analyses exploring evidence for network heterogeneity
without specifying a grouping factor a priori (i.e., in an unsupervised manner)
we used multivariate mixture models as implemented in the R module flexmix
[Leisch, 2004] [Grn and Leisch, 2008] [Grn and Leisch, 2007]. For the multivariate
mixture models, we hypothesized that groups identified in the data had different
covariance (correlation) structures reflecting the strength of the associations of the
expression values of genes within networks. We tested for the existence of two
groups in the data, but our approach could have easily tested for three or more
groups; however, sample size limitations would have resulted in poor power for such
analyses. Based on the patterns of the correlations between expression levels of the
genes within each group, we sought to identify blocks of highly correlated genes
by using simple hierarchical clustering of the pairwise correlations. Dendrograms
or trees reflecting this clustering could then be cut at varying heights to assess the
extent of heterogeneity within the flexmix analysis-derived groups.
5.3.4 Assessing Statistical Significance
In order to determine whether there was a significant statistical evidence
for subgroups within a data set regulated exhibiting different transcriptional net-
works, we leveraged simulation-based tests. For a given analysis, we simulated
1000 samples with an n-dimensional mean vector and an n x n covariance matrix
consistent with the observed mean vectors and covariance matrices for the full
data set (i.e., under the assumption of homogeneity or non-subgroups). We then
used flexmix to identify two subgroups with these simulated data sets. From these
flexmix analyses, we calculated t-statistics comparing the estimated mean vectors,
χ2 statistics comparing correlation matrices, as well as log-likelihood ratios, delta
AICs, and delta BICs comparing the two group vs. single group fits. We calculated
p-values for the statistics obtained from the non-simulated data as the number of
simulated sample statistics greater than the actual test statistics divided by 1001.
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5.3.5 A Posteriori Supervised Analyses
To determine whether or not the two groups identified in an analysis could
be explained by the existence of gene mutations present or not in the cell lines,
we performed logistic regression analysis with the flexmix group identifier for a
cell line as the dependent variable and BRAF, NRAS, and KRAS mutation in-
formation on those cell lines as explanatory variables. For the CCLE cell lines,
additional association tests were pursued using gene mutation, gene amplification,
insertion and deletion information as independent variables. To account for the
multiple hypothesis tests, we used Q:Q-plots and Benjamini-Hochberg [Benjamini
and Hochberg, 1995] FDR-adjusted p-values.
5.3.6 Exploring Network Architecture
To determine whether particular genes exhibited stronger correlations with
other genes and were acting as potential “hubs” within the transcriptional net-
works, we calculated network centrality metrics for each gene. To do this, individ-
ual “edges” between each pair of nodes (i, j ; where i and j denote genes or nodes
in the transcriptional network) were set equal to:
Eij =
0, if ρ(r2ij) > .05r2ij, otherwise
where r2ij reflects the correlation between genes i and j and ρ(r
2
ij) is the
p-value associated with that correlation, to create graphs of the network. These
calculations were performed for each group identified from the mixture analysis
using flexmix. Based on the resulting graphs, we then calculated the metrics degree
centrality, closeness centrality, betweenness centrality, and eigenvector centrality
for each gene within each groups network. With these metrics for each gene, we
examined the degree of similarity of genes across groups (i.e., we compared the
metrics for each gene across the mixture model-derived groups). For those genes
that emerged as the most central for each network, we identified drugs that target
those genes using the Drug Gene Interaction Database (DGIdb).
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5.3.7 Analyses of the CCLE Melanoma Cell Line Expres-
sion Data
To assess evidence for network rewiring associated with groups of tumors
defined by mutational status (i.e., a supervised analysis), we tested the equality of
correlation matrices computed for each group using correlation matrix equivalence
tests. Specifically, we extracted gene networks centered on BRAF and KRAS genes
using geneMANIA. For this analyses, we identified the 20 most inter-connected
genes associated with the BRAF and KRAS pathways. Although NRAS is a more
common mutation in melanomas, we pursued more focused analysis on the KRAS
mutation because the cell lines and patient splits had a greater proportion of KRAS
mutant samples (i.e., there were enough KRAS samples to pursue an analysis, but
only a limited number of NRAS mutant samples). We then calculated the pair-
wise spearman correlations for the gene expression values for those genes within
mutant melanoma cell lines and wild type melanoma cell lines. We compared the
resulting correlation matrices through permutation-based tests (see above). We
calculated χ2 statistics using the Steiger and Jennrich correlation equivalence test
methods with the psych [Revelle, 2015] package in R. As noted in the package
manual, the Steiger method uses the sum of the squared correlations, whereas the
Jennrich method compares the differences between two matrices to the averages
of the two matrices. Thus, the Steiger method emphasizes non-zero values to a
greater degree, whereas the Jennrich method places a greater emphasis the change
in correlations. We generated null distributions of χ2 statistics through permu-
tations of the mutation status. For each test, we randomly permuted mutation
status 10,000 times, repeated the analyses, and derived the distribution of test
statistics from these permutations to get a null distribution as well as p-values for
χ2 statistics.
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5.3.8 Analyses of the TCGA Melanoma Tumor Gene Ex-
pression Data
We performed similar correlation and permutation-based tests within the
TCGA melanoma gene expression data. For each melanoma patient’s tumor gene
expression data in the TCGA, we obtained expression profiles from normal and
tumor from Cancer Genomics Hub. We used BAM slicer to identify BRAF and
KRAS gene regions and we assigned somatic mutation status using the default
settings in VarScan. We stratified patient samples into three groups: BRAF mu-
tant (BRAF+), BRAF V600E mutant (BRAF V600E+), and BRAF wildtype
(BRAF-). We then performed correlation equivalence tests to compare BRAF+
against BRAF- derived spearman correlation matrices and BRAF V600E+ against
BRAF- derived spearman correlation matrices. As before, we generated null distri-
butions of relevant chi2 statistics by permuting the mutation status. To determine
whether evidence for rewiring was limited to the extracted BRAF network, we
explored evidence for broader network differences by identifying genes that exhib-
ited differential expression between mutant and wild type groups using the DESeq
and edgeR packages in R. We used these genes as inputs to identify candidate
networks by assessing them with geneMANIA and GO. Resulting networks were
then assessed for differences across the mutation-defined groups, using correlation
equivalence tests and degree centrality statistics on these additional DEG-derived
networks.
5.3.9 Network Reconstruction Analyses
As a complement to analyses comparing correlation matrices, we used the
Weighted Gene Correlation Network Analysis [Langfelder and Horvath, 2008] [Langfelder
and Horvath, 2012] (WGCNA) package in R to identify significant transcriptional
“modules” within mutation bearing and non-mutation-bearing samples. We cre-
ated modules (setting WCGNA parameter k to k = 10 and k = 20) within
BRAF+/- and KRAS+/- groups for the SU2C melanoma cell lines; and BRAF+/-
and BRAF V600E+/BRAF- for the TCGA patient tumor samples. Correspond-
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ing modules were defined as the modules with the maximum overlapping gene
matches between BRAF- or KRAS- modules and BRAF+, BRAF V600E+, or
KRAS+ modules. For the intersections of genes identified, we assessed network
rewiring using the previously mentioned node centrality statistics and correlation
equivalence tests.
5.4 Results
5.4.1 Unsupervised Multivariate Mixture Model Analysis
of the Transcriptomes of Melanoma Cell Lines
As noted in the Methods section, we extracted genes from the WikiPathway
version of the MAPK pathway (n = 224). These 224 genes were then mapped to
the probesets used in the Affymetrix gene expression chips applied to the CCLE
and TGen cells lines based on the maximum average intensity for each gene (Sup-
plemental Table 2). We also obtained gene expression levels for these genes from
the RNA-seq data available on the TCGA melanoma samples. However, only 216
or these 224 genes could be confidently mapped to the TCGA RNAseq data. We
applied flexmix to identify gene expression-based clusters in the SU2C melanoma
cell lines. Across different datasets two groups consistently emerged. For the SU2C
cell lines the two groups emerging from this analysis were made up of 27 and 7
cell lines. In applying it to the CCLE melanoma cell line group sizes of 39 and 19
were identified (Table 5.1). Moreover, for the TCGA data, the two groups were
made up of 401 and 72 tumors. When all the CCLE cell lines were considered
together the groups emerging had 375 and 542 cell lines. Density plots for the
posterior probability of the flexmix groups revealed that the clusters were most
distinct in the SU2C melanoma cell lines (Figures 5.9A-B). This is also evident
when viewing the number of edges present when comparing graphs with identical
nodes (Figure 5.10). Interestingly, when we used permutation tests to assess the
statistical significance of the mean gene expression levels between the two groups
we found that mean equality tests were not significant. However, tests of the
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equality of the correlation matrices between the two groups yielded statistically
significant p-values for the TCGA melanoma patients and the CCLE all cell lines
cohort, moderately significant p-values for the CCLE melanoma cell lines, and a
non-significant p-value for the SU2C melanoma cell lines. However, we found that
in each cohort, the mixture groups were significant in at least one statistic (LLR,
delta AIC, or delta BIC, Table 5.1).
In order to visualize the relationships between the genes based on their
expression levels and assess their consistency across the two groups identified in
each data set, we extracted pairwise spearman correlation coefficients from the
correlation matrices and then generated heatmaps on the matrices in which the
entries above the diagonal were from one group set and those below the diagonal
were from the other (Figures 5.2A-D, Figure 5.11, Figure 5.12). If the correlations
were the same the matrices would be completely symmetric. Clearly, the heatmaps
suggest differences exist between the flexmix clusters in each of the data sets,
although the differences were more pronounced in the SU2C melanoma cell lines
and the CCLE melanoma cell lines.
5.4.2 Does Mutation Status Explain the Clustering?
To assess whether common factors in melanoma cell lines and tumors ex-
plain the mixture model clustering, we performed logistic regression using BRAF
and KRAS mutation status as predictors of cluster membership; BRAF and NRAS
mutation status for the CCLE melanoma cell line cluster membership; and the
BRAF V600E mutation status for the TCGA patient samples cluster membership.
In each analysis, we found that the mutation status was not a significant predictor
of the clusters (Table 5.2). For the CCLE cell lines, we also performed logistic
regression with copy number variation, mutation, insertion, and deletion status as
predictors of cluster membership. Interestingly, for the subset of melanoma cell
lines in the CCLE data, the QQ-plots and FDR-adjusted p-values did not indicate
any significant predictors of the cluster (Figure 5.9C), although over the entire set
of CCLE cell lines, the QQ-plots and FDR-adjusted p-values did suggest that ge-
netic variations could predict or explain the two groups that were identified (Figure
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Table 5.1: Comparing a priori called clusters within SU2C melanoma cell lines
(MCL), CCLE MCL, CCLE all cell lines (ACL), and TCGA melanoma patients.
Performed mean vector and covariance equality tests within groups and used log-
likelihood ratio permutation-based tests to evaluate strength of one, two, or three
groups.
Mean Equality Test SU2C MCL CCLE MCL CCLE ACL TCGA Mel
T-Test Statistic 4.9867 6.144 6.5957 4.314
df 223 223 223 216
p-value 1.23E-06 3.66E-09 3.03E-10 2.44E-05
Simulation p-value 0.309327 0.4325581 0.3452381 0.3583333
Correlation Equality Test SU2C MCL CCLE MCL CCLE ACL TCGA Mel
Chi-sq Statistic 1320.269 1915.88 66408.1 76275.79
df 561 1653 22791 22366
p-value 4.30E-63 6.50E-06 0 0
Simulation p-value 0.08891109 0.04595405 0.000999001 0.000999001
Flexmix 2 groups vs. 1 group SU2C MCL CCLE MCL CCLE ACL TCGA Mel
LLR Statistic 9.349944 0.444172 9.479712 34.39548
LLR Permuted P-Value 0.008991009 0.3786214 0.01298701 0.000999001
Delta AIC Statistic -3.349944 5.555828 -3.479712 -28.39548
Delta AIC Permuted P-Value 0.008991009 0.3796204 0.01298701 0.000999001
Delta BIC Statistic 1.229137 11.73716 10.98361 -15.9182
Delta BIC Permuted P-Value 0.000999001 0.02897103 0.03196803 0.000999001
Flexmix 3 groups vs. 1 group SU2C MCL CCLE MCL CCLE ACL TCGA Mel
LLR Statistic 9.354378 0.5115797 9.557176 39.45247
LLR Permuted P-Value 0.02797203 0.4825175 0.02997003 0.000999001
Delta AIC Statistic 2.645622 11.48842 2.442824 -27.45247
Delta AIC Permuted P-Value 0.02797203 0.4825175 0.02997003 0.000999001
Delta BIC Statistic 11.80379 23.85108 31.36947 -2.497894
Delta BIC Permuted P-Value 0.000999001 0.00999001 0.1048951 0.000999001
106
A. B.
C. D.
Figure 5.2: Pairwise correlation between MAPK Pathway genes from the identi-
fied clusters using flexmix were used to generate heatmaps. Upper right hand half
of matrix were correlation coefficients from cluster 1, whereas lower left hand half
of matrix were correlation coefficients from cluster 2. Heirarchical clustering was
subsequently performed using either distances from cluster 1 coefficients (panels
A, C) or cluster 2 coefficients (panels B, D). (A) and (B) are from flexmix derived
clusters on SU2C melanoma cell lines (C) and (D) are flexmix derived clusters on
CCLE melanoma cell lines.
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Table 5.2: Table of association test results between a priori called clusters and
common factors in melanoma. We test against available mutation status TCGA
melanoma patients, SU2C melanoma cell lines, and CCLE melanoma cell lines.
SU2C MAPK Pathway Cluster
Mutation Estimate Std. Error z value Pr(>—z—)
BRAF +/- 0.2136 0.8554 0.25 0.8028
KRAS +/- 0.3365 0.9562 0.352 0.72492
TCGA MAPK Pathway Cluster
Mutation Estimate Std. Error z value Pr(>—z—)
BRAF v600e +/- -0.1234 0.2786 -0.443 0.658
CCLE Melanoma Cell Lines MAPK Pathway Cluster
Mutation Estimate Std. Error z value Pr(>—z—)
BRAF +/- -0.2231 0.8878 -0.251 0.8016
NRAS +/- -0.5522 0.9289 -0.594 0.552
5.9D). These results were similarly observed when regressing on the clusters with
copy number variation (Figure 5.13), suggesting that the gene expression associa-
tions identified across the entire CCLE cohort potentially arose from copy number
variation.
5.4.3 Degree Centrality Analysis
For each group or cluster identified from the multivariate mixture model
analysis (for k = 2 groups), we tested the statistical significance of the pairwise gene
correlations (where edges were kept if ρ(r2ij)≤ .05). We then removed all edges (i.e.,
gene pairs) without a significant correlation. We calculated the degree centrality
statistics on the genes based on the remaining correlation strengths. The more
connected or central genes were then extracted based on each degree centrality
statistic and mapped to the Drug Gene Interaction Database (Table 5.3). This
analysis suggested Bortezomib and Carfilzomib as potential drug targets in one
of the clusters identified for each of the SU2C, CCLE melanoma, and all CCLE
all cell lines. However, this same analysis applied to the second cluster for each
of these data sets suggested that different drugs (Tofacitinib, AT9283, AZD1480,
108
Table 5.3: Network node centrality statistics identified central nodes for each
parameter. Consensus-based approach was used to genes to match to DGIdb to
identify candidate therapeutic agents.
Dataset Degree Closeness Betweenness Eigenvector
SU2C K1 201274 at (PSMA5) 201274 at (PSMA5) 201274 at (PSMA5) 201532 at (PSMA3)
SU2C K2 227677 at (JAK3) 227677 at (JAK3) 201648 at (JAK1) 227677 at (JAK3)
CCLE Mel K1 201388 at (PSMD3) 201979 s at (PPP5C) 201388 at (PSMD3) 201388 at (PSMD3)
CCLE Mel K2 226163 at (SYNGAP1, ZBTB9) 226163 at (SYNGAP1, ZBTB9) 207243 s at (CALM2) 226163 at (SYNGAP1, ZBTB9)
CCLE All K1 201274 at (PSMA5) 201274 at (PSMA5) 201274 at (PSMA5) 201274 at (PSMA5)
CCLE All k2 208799 at (PSMB5) 208799 at (PSMB5) 208799 at (PSMB5) 201400 at (PSMB3)
TCGA Mel K1 x819 (APBB1IP) x14671 (RASGRF1) x14671 (RASGRF1) x819 (APBB1IP)
TCGA Mel K2 x819 (APBB1IP) x14632 (RAP1A) x14632 (RAP1A) x819 (APBB1IP)
Dataset Consensus Predicted Drug Targets
SU2C K1 PSMA5 BORTEZOMIB, CARFILZOMIB
SU2C K2 JAK3 TOFACITINIB, AT9283, AZD1480, PACRITINIB, TOFACITINIB CITRATE
CCLE Mel K1 PSMD3 BORTEZOMIB, CARFILZOMIB
CCLE Mel K2 SYNGAP1, ZBTB9 NA
CCLE All K1 PSMA5 BORTEZOMIB, CARFILZOMIB
CCLE All k2 PSMB5 BORTEZOMIB, CARFILZOMIB, OPROZOMIB
TCGA Mel K1 APBB1IP, RASGRF1 NA
TCGA Mel K2 APBB1IP, RAP1A NA
Pacritinib, Tofacitinib, and Citrate) would be better candidates, as least based
on the connectedness or centrality of the genes given the identified transcriptional
correlation strengths or networks. For the CCLE melanoma cell lines and the
TCGA tumors, no drugs were identified based on this analysis for the second
group. Finally, we compared the overall degree centrality statistic, across all the
data sets to assess their consistency (Figure 5.3). These density plots revealed
that network rewiring was more pronounced in the SU2C melanoma cell lines and
the CCLE melanoma cell lines, as there was a more obvious mixture of densities
in these cohorts in the plots. The density plots for the TCGA samples and the
complete set of cell lines for the CCLE data set were very similar and indicated
that the differences in identified networks were again not as pronounced (Figures
5.15-5.16). This is likely due to the heterogeneity between TCGA patient samples
and cross tissue pan-CCLE analysis (i.e., the cell lines are from different tissues,
thus likely have very different underlying baseline networks).
5.4.4 Are the Networks Equivalent for Mutation Status
Defined Groups Against Normal Controls?
We tested the possibility that network rewiring occurs as the consequence of
mutation (i.e., the subgroups identified with supervised clustering were associated
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Figure 5.3: Density plots of degree centrality parameters. Figures (A)-(D) are
based on analysis of SU2C melanoma cell lines and figures (E)-(H) are based on
analysis of CCLE melanoma cell lines. The plots are densities of centrality for (A)
and (E), closeness for (B) and (F), betweenness for (C) and (G), and Eigenvector
centrality for (D) and (H).
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with the presence of a specific mutation). We first tested the equality of the
correlation matrices derived from groups defined by mutation status for each data
set defined by: BRAF+, BRAF-, KRAS+, and KRAS- against correlation matrices
derived from skin fibroblast control gene expression data (as previously described in
the methods section). Based on these matrix equivalency tests, we found evidence
for statistically significant rewiring when comparing BRAF+, BRAF-, and KRAS-
defined cell lines against skin fibroblast data (Table 5.4). However, when testing
the KRAS+ against the control groups, the correlation matrix differences was not
statistically significant from that derived from the skin fibroblast data (this may
have been a result of the small sample size for the KRAS+ cell lines; n = 8).
When we tested the equivalence of correlation matrices across BRAF and
KRAS mutation status defined groups within each data set, we found evidence for
statistically significant differences based on tests that involved permuting mutation
status (Table 5.4). We used differential correlations between mutant-defined and
wild type-defined groups to assess the overall degree of rewiring. For the BRAF-
associated genes, we found strong correlation differences between BRAF+ and
BRAF- groups within a small set of gene pairs. However, for the KRAS-associated
genes, roughly half of the genes pairs exhibited statistically significant correlation
changes when assessing differences between KRAS+ and KRAS- groups (Figures
5.4A-B). Interestingly, when we considered the genes defined in the BRAF network
for the TCGA melanoma samples, we also observed differences when comparing
BRAF+/BRAF- derived correlation matrices as well as BRAF V600E+/BRAF-
derived correlation matrices (Jennrich method significant, p-val < .027 and p-val
< .032, respectively; Table 5.4). However, when we used VarScan to call the
somatic mutation status and assign mutation status to the patient tumor samples,
the signal from the matrix equivalence test was lost, suggesting that the network
equivalence changes were only observable in the filtered samples.
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Figure 5.4: Differential pairwise correlation of (A) BRAF associated genes differ-
entiated by BRAF mutation status and (B) KRAS associated genes differentiated
by KRAS mutation status.
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Table 5.4: Table of correlation equality tests for the genes in the specified net-
works. Tests are between mutant and wild type samples. Asterisks represent at
least one significant test within comparison (Stieger or Jennrich).
Dataset Samples Network St Chi-sq Sim Mut St pval JR Chi-sq Sim Mut JR pval Sig in 1 model?
TGen Cell Line BRAF+/- BRAF GM 209 0.019 802 0.754 *
BRAF+/control BRAF GM 316.9404 0.00909909 972.9073 0.2678732 *
BRAF-/Control BRAF GM 333.675 0.00309969 670.7589 0.8981102 *
KRAS+/Control BRAF GM 228.3091 0.1333195 1086.123 0.6022398
KRAS-/Control BRAF GM 373.2865 0.00049995 792.552 0.3406659 *
KRAS+/- KRAS GM 158 0.437 678 0.042 *
BRAF+/control KRAS GM 310.6259 0.00629937 722.1048 0.820018 *
BRAF-/Control KRAS GM 285.9183 0.01479852 706.6058 0.910309 *
KRAS+/Control KRAS GM 207.9291 0.2406963 1077.38 0.7448255
KRAS-/Control KRAS GM 338.746 0.00079992 535.796 0.9529047 *
TCGA Samples BRAF+/- BRAF GM 673 0.1812 1325 0.0269 *
BRAF V600E +/BRAFwt BRAF GM 658 0.2263 1332 0.0319 *
TCGA (WT somatic calls) BRAF+/- (add somatic called) BRAF GM 636 0.3107 1195 0.3592
BRAF V600E +/BRAFwt BRAF GM 625 0.3643 1236 0.2996
BRAF V600E +/BRAFwt 26 DEGs GM 19513.81 0.01887179 92424.32 0.9985938 *
5.4.5 BRAF V600E+/- Differentially Expressed Genes Anal-
ysis with the Melanoma TCGA Tumor Data
We identified genes that exhibited average gene expression level differences
between BRAF V600E+ and BRAF- tumor samples in the entire TCGA data
using DESeq (FDR adjusted p < .05) and edgeR (FDR < .01) between and iden-
tified 26 differentially expressed genes (DEGs) (Table 5.4). These genes were then
used to extract a new gene network from geneMANIA. As anticipated, when we
compared the correlation matrices based on the genes in this new network be-
tween BRAF+ and BRAF- groups, we observed statistically significant network
changes. However, an analysis of the GO networks derived from these genes pro-
duced mostly non-significant differences between the BRAF V600E+ and BRAF-
patient samples. These results indicate that the patient-specific network rewiring
may have been isolated to specific nodes and were less pronounced than compar-
isons to the melanoma cell lines. To further investigate the overall differences in the
correlations among gene expression levels between the TCGA BRAF V600E+/-
samples, we calculated the spearman correlation between 348 DEGs (edgeR FDR
< .01 and DESeq FDR-adjusted p-value < .05) and all other genes we had expres-
sion level data on. Using a strict Bonferroni-adjusted significance threshold, we
observed 63,118 (0.88%) significant gene correlations in BRAF V600E+ patients,
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81,765 (1.14%) significant gene correlations in BRAF- samples, and 21,844 (0.31%)
significant gene pairs in common. Overall, we found that the majority of the sig-
nificant gene pair correlations were significant in only one of the groups (Figure
5.16), further indicating that the correlation strengths and overall transcriptional
networks between TCGA BRAF V600E+ and BRAF- tumor samples are unique.
5.4.6 Network Centrality Tests for the TGen Melanoma
Cell Lines
To investigate the importance of individual genes or pairs of genes in the
transcriptional correlation networks we observed in our analyses of the TGen
melanoma cell line data, we calculated the node centrality statistics for each net-
work. These analyses suggested that the most important genes associated with
BRAF+ cell lines for all genes in the BRAF network were ARAF, RAF1, and
OIPS; whereas the most central or connected genes in the BRAF- cell lines were
RAF1 and HRAS (Figure 5.17, Figure 5.18, and Table 5.5). For the genes in the
BRAF geneMANIA-derived network, the average correlation across all node cen-
trality statistics was 0.1121 for BRAF+/- and 0.0001 for KRAS+/- indicating the
existence of different central nodes (Table 5.5) for the networks. For the KRAS
geneMANIA network, we observed negative correlations when comparing them
across KRAS+/- cell lines for all node centrality statistics, which indicates that
extensive transcriptional rewiring is occuring in the networks. Additionally, based
on the genes that appeared as most central to the identified networks, DGIdb anal-
ysis suggested different drug targets. For the BRAF+ cell lines, the most central
or connected genes in the networks indicated that MEK inhibitors would be likely
candidate drugs (Table 5.5). However, for the BRAF- cell lines, mTOR inhibitors
were predicted as best targets.
5.4.7 Network Centrality Tests for the TCGA Data
Centrality and connection analysis of the TCGA patient samples based
on BRAF mutation status also identified distinct central genes in transcriptional
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Table 5.5: Assessing significant nodes by degree centrality parameters. A
consensus-based approach was used to genes to match to DGIdb to identify can-
didate therapeutic agents.
Dataset Samples Network DC BW CL EC Consensus Predicted Drug Targets (Top Genes Only)
TGen Cell Line BRAF+ BRAF GM ARAF ARAF RAF1, ARAF, OIPS ARAF ARAF Sorafenib, Trametinib, Regorafenib, BMS-908662, Adenosine Triphosphate
TGen Cell Line BRAF- BRAF GM HRAS RAF1, HRAS RAF1, HRAS HRAS HRAS AZD8055, Everolimus, DB08751
TGen Cell Line KRAS+ KRAS GM RASSF2, RGL2 RASSF2, RGL2 RASSF2, RGL2 RASSF2, RGL2 RASSF2, RGL2
TGen Cell Line KRAS- KRAS GM NTF3 NTF3 NTF3 NTF3 NTF3
TCGA Samples BRAF+ BRAF GM CCDC88A CNKSR1 CNKSR1 CCDC88A CCDC88A, CNKSR1
TCGA Samples BRAF V600E+ BRAF GM CCDC88A CNSKR1 RHEBL1 CCDC88A CCDC88A
TCGA Samples BRAF- BRAF GM RAP2C RHEBL1 RAP2C RAP2C RAP2C
TCGA Samples BRAF V600E+ 26 DEGs GM ATF1, CSTF3, GTG2E1, GFT2E2, GTF3A, PHTF2, TFEC, TFPI, TF, BCL2L15, FAM3C, PMCHL1 BCAP29 CSTF3 BCAP29 BCAP29
TCGA Samples BRAF- 26 DEGs GM TFPI BCAP29 TFPI BCAP29 TFPI, BCAP29
networks. Although there was a strong positive correlation for each node cen-
trality statistic (r > .48) across BRAF+ and BRAF V600E+ when compared
against BRAF-, the networks derived from the gene expression-based correlation
coefficients for BRAF+ patients had CCDC88A and CNKSR1 as most central or
connected genes, whereas networks derived from BRAF V600E+ samples had only
CCDC88A as the most important node (Figure 5.5, Figure 5.19, and Table 5.6).
CCDC88A is a key modulator of the AKT-mTOR signaling pathway [UniProt
Consortium, 2015] and CNKSR1 promotes invasion of cancer cells through NFB
dependent signaling [Fritz and Radziwill, 2010] (Table 5.5). For the BRAF- de-
rived networks, the central node was found to be RAP2C, which is a RAS-related
protein in the MAPK/ERK signaling pathway. The consensus central nodes for
melanoma cell lines with and without BRAF mutations were mapped to candidate
drugs using DGIdb. Interestingly, RAF and MEK inhibitors (Sorafenib, Tram-
etinib, Regorafenib, BMS-908662, and Adenosine Triphosphate) were predicted
to be the best drugs give the observed BRAF+ transcriptional network, whereas
the mTOR inhibitors (AZD8055, Everolimus, and DB08751) were predicted to be
the best drugs in the observed BRAF- transcriptional network (Figures 5.19-5.21,
Table 5.5).
5.4.8 Are Strong Edges Present in Both Mutant and Wild
Type Groups?
To evaluate the strength of the correlation coefficients obtained, we assessed
the overall distribution of coefficients (Figure 5.24). We found that the distribution
of pairwise correlation for BRAF-associated genes were approximately the same
in both BRAF+ and BRAF- subgroups. However, when evaluating the KRAS-
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Figure 5.5: Network centrality statistics identifying differential central nodes be-
tween BRAF+ and BRAF- patients from TCGA data. (A) Degree Centrality, (B)
Closeness Centrality, (C) Betweenness Centrality, and (D) Eigenvector Centrality
can all be used to assess different properties of the network.
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Table 5.6: A comparison between degree centrality parameters through corre-
lations. DC = Degree Centrality, BW = Betweenness, CL = Closeness, EC =
Eigenvector Centrality.
Dataset Samples Network DC Cor BW Cor CL Cor EC Cor Avg Cor
TGen Cell Line BRAF+/- BRAF GM 0.05340418 0.1522432 0.1027221 0.1401849 0.112138595
TGen Cell Line KRAS+/- BRAF GM 0.103506 0.03017858 0.003084305 -0.1362763 0.000123146
TGen Cell Line BRAF+/- KRAS GM -0.06479926 -0.09663954 -0.3566459 -0.4211979 -0.23482065
TGen Cell Line KRAS+/- KRAS GM -0.5021395 -0.1873172 -0.5892824 -0.3236824 -0.400605375
TCGA Samples BRAF+/- BRAF GM 0.7678829 0.2597188 0.28202 0.8450726 0.538673575
TCGA Samples BRAF V600E +/BRAFwt BRAF GM 0.777453 0.363136 0.4762343 0.8624035 0.6198067
TCGA (WT somatic calls) BRAF+/- (add somatic called) BRAF GM 0.7786251 0.5123316 0.4362009 0.8747135 0.650467775
TCGA (WT somatic calls) BRAF V600E +/BRAFwt BRAF GM 0.7920405 0.6776392 0.6469417 0.8510963 0.741929425
TCGA (WT somatic calls) BRAF V600E +/BRAFwt 26 DEGs GM 0.2356217 0.8135823 0.3493597 0.4647389 0.46582565
associated genes, there was an increased proportion of correlation coefficients near
the tail for KRAS+ subgroup when compared against the KRAS- subgroup, which
suggests a stronger network in the KRAS+ subgroup exists. This is further con-
firmed when assessing the upper 5% tail in correlation coefficients (for BRAF-
associated genes, r = .54 in both BRAF+/BRAF- subgroups; for KRAS-associated
genes, r = .46 in KRAS- subgroup and r = .76 for KRAS+ subgroup).
To assess whether the strongest co-expression patterns were observed in
normal laboratory conditions, we extracted all correlation coefficients less than
-.7 or greater than .7 (Table 5.9). We then used the resulting gene list as an
input into geneMANIA in order in order to calculate the proportion of edges that
were previously reported. Surprisingly, we found that a majority of the strong co-
expression edges were not previously identified (Figure 5.25). Specifically, for the
BRAF- subgroup, RAP2B and RAP2C are co-localized and share protein domains;
for the BRAF+ subgroup, BRAF and RHEB are in the same pathway and have
physical interactions; and for the KRAS+ subgroup, RALA and UBE2K are co-
expressed, KRAS and RASSF2 have physical interactions, RGL2 and KRAS are
in the same pathway and have physical interactions, and RASSF2 and APBB1IP
have shared protein domains. Thus, only six of the 24 identified strong edges were
previously reported.
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5.4.9 De Novo Network Reconstruction Analysis
We also considered reconstructing transcriptional networks de novo using
WCGNA [Langfelder and Horvath, 2008] [Langfelder and Horvath, 2012] across
mutation-status (supervised) groups on the TGen melanoma cell lines and TCGA
melanoma patient samples. For the TGen melanoma cell lines, WGCNA modules
were created using BRAF and KRAS mutation groupings (Figure 5.6A-B, 5.22).
For each of the modules identified from the WCGNA assessment of the wild-type
cell lines, we identified the modules identified in the mutation-bearing cell lines
with the highest intersection of genes. We then tested these intersecting genes for
network rewiring using network equivalence and permutation tests (although we
were unable to test for KRAS because of the limited number of KRAS+ melanoma
cell lines). Our results confirmed the network rewiring on the de novo reconstructed
networks (Table 5.7). When creating ten modules for the melanoma cell lines, six
out of the ten networks had strong p-values; and when creating twenty modules
for the melanoma cell lines, seven out of the 20 networks had strong p-values. Al-
though the network rewiring in the TCGA patients was not as extensive, there were
still some modules that had statistically significant p-values (Figure 5.6C, Figure
5.23 and Table 5.7). We found that there was network rewiring in a small number
of a priori created modules in both BRAF+ vs. BRAF- and BRAFV600E+ vs.
BRAF- melanoma cohorts.
5.5 Discussion
Although there has been a great deal of attention given to the develop-
ment and use of pathway and genetic network analysis tools in understanding
disease pathogenesis and drug targeting, these tools often rely upon the use of
pathway and network information derived from analyses of genes in normal and
non-diseased cells, cell lines and tissues [Hofree et al., 2013] [Jung and Kim, 2014]
[Mootha et al., 2003] [Subramanian et al., 2005]. This compromises relevant anal-
yses since pathways and genetic networks are not static and are often perturbed
by various diseases of interest in those analyses. This is especially true in the
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Figure 5.6: WGCNA derived modules used for a priori assessment of net-
work rewiring. (A) Beanplots of overlapping modules between melanoma cell
line BRAF+/- (red) and random permutation-based (gray) overlap (B) Beanplots
of overlapping modules between melanoma cell line KRAS+/- (blue) and ran-
dom permutation-based (gray) and (C) Beanplots of overlapping modules between
TCGA melanoma patient BRAF+/- (red) and BRAFv600e+/- (dark red) overlap
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Table 5.7: Correlation equality tests between WGCNA defined modules
in BRAF+/- SU2C cell lines, BRAF+/- TCGA melanoma patients, and
BRAFv600e+/- TCGA melanoma patients.
SU2C Cell Lines: BRAF+ vs BRAF- TCGA Melanoma Patients: BRAF+ vs BRAF- TCGA Melanoma Patients: BRAFv600e+ vs BRAF-
WGCNA Module Network Size St Chi-sq Sim Mut St pval WGCNA Module Network Size St Chi-sq Sim Mut St pval WGCNA Module Network Size St Chi-sq Sim Mut St pval
WGCNA 1 (k = 10) 177 21137 0.003 WGCNA 1 (k = 10) 388 104850.9 0.05494505 WGCNA 1 (k = 10) 375 90564.64 0.1248751
WGCNA 2 (k = 10) 210 22813 0.152 WGCNA 2 (k = 10) 374 80097.34 0.2507493 WGCNA 2 (k = 10) 379 81201.04 0.2617383
WGCNA 3 (k = 10) 363 NA WGCNA 3 (k = 10) 311 46890.96 0.5984016 WGCNA 3 (k = 10) 304 46140.55 0.5124875
WGCNA 4 (k = 10) 173 21100 0.001 WGCNA 4 (k = 10) 203 26916.43 0.1318681 WGCNA 4 (k = 10) 289 59361.26 0.1248751
WGCNA 5 (k = 10) 146 9770 0.135 WGCNA 5 (k = 10) 375 103328.7 0.1298701 WGCNA 5 (k = 10) 380 106081.3 0.1278721
WGCNA 6 (k = 10) 151 12584 0.042 WGCNA 6 (k = 10) 100 5847.691 0.08191808 WGCNA 6 (k = 10) 100 7580.433 0.001998002
WGCNA 7 (k = 10) 139 10240 0.044 WGCNA 7 (k = 10) 432 110979.6 0.2277722 WGCNA 7 (k = 10) 462 133053.9 0.1668332
WGCNA 8 (k = 10) 106 6058 0.002 WGCNA 8 (k = 10) 75 4024.792 0.04195804 WGCNA 8 (k = 10) 73 4256.042 0.02397602
WGCNA 9 (k = 10) 261 27640 0.343 WGCNA 9 (k = 10) 282 54268.77 0.04195804 WGCNA 9 (k = 10) 346 79351.82 0.06293706
WGCNA 10 (k = 10) 165 16857 0.069 WGCNA 10 (k = 10) 185 18780.28 0.3806194 WGCNA 10 (k = 10) 184 18863.78 0.3366633
WGCNA 1 (k = 10) 115 6637 0.183 WGCNA 1 (k = 20) 127 9636.389 0.1228771 WGCNA 1 (k = 20) 128 10609.87 0.06693307
WGCNA 2 (k = 20) 86 2174 0.987 WGCNA 2 (k = 20) 161 13476.35 0.5004995 WGCNA 2 (k = 20) 159 12823.37 0.5134865
WGCNA 3 (k = 20) 41 868 0.121 WGCNA 3 (k = 20) 139 8823.917 0.7122877 WGCNA 3 (k = 20) 136 8576.759 0.7122877
WGCNA 4 (k = 20) 50 1693 0.007 WGCNA 4 (k = 20) 160 12930.49 0.4565435 WGCNA 4 (k = 20) 140 10142.85 0.4185814
WGCNA 5 (k = 20) 38 731 0.089 WGCNA 5 (k = 20) 138 10935.09 0.2257742 WGCNA 5 (k = 20) 118 8564.582 0.2057942
WGCNA 6 (k = 20) 58 1269 0.563 WGCNA 6 (k = 20) 405 112287.8 0.1418581 WGCNA 6 (k = 20) 370 89285.78 0.1838162
WGCNA 7 (k = 20) 172 11040 0.481 WGCNA 7 (k = 20) 201 35418.36 0.08191808 WGCNA 7 (k = 20) 181 28131.66 0.09490509
WGCNA 8 (k = 20) 38 834 0.053 WGCNA 8 (k = 20) 105 7231.11 0.1248751 WGCNA 8 (k = 20) 159 14801.29 0.2457542
WGCNA 9 (k = 20) 58 2249 0.017 WGCNA 9 (k = 20) 171 17254.12 0.2557443 WGCNA 9 (k = 20) 173 17306.31 0.2737263
WGCNA 10 (k = 20) 48 881 0.400 WGCNA 10 (k = 20) 187 20291.88 0.2167832 WGCNA 10 (k = 20) 189 21524.95 0.1848152
WGCNA 11 (k = 20) 88 4670 0.150 WGCNA 11 (k = 20) 69 3021.248 0.1108891 WGCNA 11 (k = 20) 64 2667.571 0.0979021
WGCNA 12 (k = 20) 124 NA WGCNA 12 (k = 20) 246 34916.67 0.2657343 WGCNA 12 (k = 20) 222 28239.58 0.2717283
WGCNA 13 (k = 20) 35 971 0.003 WGCNA 13 (k = 20) 55 1602.315 0.3716284 WGCNA 13 (k = 20) 54 1688.05 0.2007992
WGCNA 14 (k = 20) 88 3814 0.215 WGCNA 14 (k = 20) 218 26417.98 0.3296703 WGCNA 14 (k = 20) 230 27211.54 0.4685315
WGCNA 15 (k = 20) 50 2179 0.016 WGCNA 15 (k = 20) 21 293.7024 0.02397602 WGCNA 15 (k = 20) 15 174.5572 0.01798202
WGCNA 16 (k = 20) 46 1193 0.049 WGCNA 16 (k = 20) 134 12282.96 0.1608392 WGCNA 16 (k = 20) 84 4154.571 0.2887113
WGCNA 17 (k = 20) 45 1638 0.023 WGCNA 17 (k = 20) 128 10300.94 0.2267732 WGCNA 17 (k = 20) 153 15411.85 0.1918082
WGCNA 18 (k = 20) 72 3108 0.077 WGCNA 18 (k = 20) 170 15247.5 0.4195804 WGCNA 18 (k = 20) 169 15297.47 0.4155844
WGCNA 19 (k = 20) 41 1211 0.016 WGCNA 19 (k = 20) 117 8769.188 0.2357642 WGCNA 19 (k = 20) 115 9200.047 0.1338661
WGCNA 20 (k = 20) 42 1030 0.056 WGCNA 20 (k = 20) 12 89.48155 0.09190809 WGCNA 20 (k = 20) 13 77.14802 0.5094905
study of cancer, where there are many stresses including gene perturbations, drugs
and environmental influences, that all impact the way genes interact and enter
into, e.g., signaling or regulatory relationships. This is not to say that researchers
cannot use information about the relationships among genes derived from studies
of normal cells and tissues as an initial starting point for detecting differences in
gene relationships in a disease state, but it does suggest that a great deal of cau-
tion should be made in making claims about the relationships between genes in a
disease state, i.e., their “wiring” as reflected in the networks they form.
We assessed evidence for network rewiring a posterori among a set of
melanoma cell lines and tumor profiles by leveraging multivariate mixture models
in the analysis of the relationships among gene expression values. The mixture
models allowed us to identify subsets of cell lines and tumors that exhibited the
most evidence for rewiring (i.e., differences in the relationships among genes based
on their expression patterns) without having to specify a priori which cell lines or
tumors we wanted to contrast for network differences. We focused on the MAPK
pathway in particular and found that, based on very robust simulation-based tests,
heterogeneity in networks reflective of rewiring did indeed exist in our cell lines
and tumor profiles. Furthermore, we explored various factors that could explain
the differences between the identified cell lines, tumor profiles identified from the
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mixture models, but found that, in the melanoma cell lines, common melanoma
gene alterations could not explain the group differences we identified, suggesting
that some other factor is responsible for the rewiring in these groups of cell lines
and tumors. We also applied degree centrality and other network node importance
statistics to the networks in the subgroups of cell lines and tumors identified. These
analyses suggested that different genes played more central roles in the different
subgroup networks and hence were likely better drug targets. These results suggest
that the use of pathway and genetic network information on a biologically relevant
subset of cell lines or tumors may reveal greater insights into drug candidates.
As a complement to using mixture models to identify novel subgroups of
melanoma cell lines and tumors exhibiting evidence for genetic network rewiring,
we also compared the genetic networks based on correlations between expression
levels of genes in melanoma cell lines and patient samples across groups defined
by the presence of specific mutations in supervised analyses. We found that there
was evidence of network rewiring when stratifying the cell lines based on mutation
status. Although network rewiring was also observed in the patient samples, it was
less pronounced. The cancer cell lines may have gone through numerous passages,
contributing to changes in genetic network and gene expression patterns. Another
potential explanation is that cell lines represent a fairly homogeneous population
with chaotic genomes, while patient tumor samples are heterogeneous with respect
to the mutations they carry and are often comprised of tumor, stroma, infiltrating
immune cells, and other non-tumor cells. It is likely that this heterogeneity makes
it much more difficult to clearly identify changes in correlation in gene expression.
Tumor heterogeneity also makes identifying consensus between-patient drug tar-
gets more difficult since patient-specific “rewiring” could affect the downstream
drug target identification.
Our analyses also involved the use of various network centrality statistics to
identify candidate genes (i.e., nodes in the networks) that might be ideal drug tar-
gets among both BRAF mutant cell lines and BRAF wild-type cell lines, especially
for groups defined (in a supervised manner) by mutation status. As expected, we
found that MEK inhibitors were the most likely drugs to affect BRAF mutant cell
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lines, whereas the mTOR inhibitors were the most likely drugs to affect BRAF
wild-type cell lines. Ultimately, we feel that our analyses strongly suggest that an
understanding of how the relationships among genes or other factors influencing,
or associated with, disease pathogenesis can facilitate treatment decisions. How-
ever, the identification of these relationships requires a clear sensitivity to the fact
that those relationships change in the disease state in ways that cannot be easily
anticipated from, e.g., mutation status or average gene expression levels alone.
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5.7 Supplemental Figures
Figure 5.7: Boxplot of normalized gene expression profiles across all melanoma
cell lines and skin fibroblast samples.
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Table 5.8: List of skin fibroblast samples obtained from GEO. Sample repository,
sample name, and associated meta data is provided.
GEO Datset Sample ID Sample Label
GSE70818 GSM1820029 Normal 0J
GSE70818 GSM1820030 Normal 0.5J 4hr
GSE70818 GSM1820031 Normal 0.5J 12hr
GSE70818 GSM1820032 Normal 5J 4hr
GSE70818 GSM1820033 Normal 5J 12hr
GSE41751 GSM1023557 Father rep1
GSE41751 GSM1023558 Father rep2
GSE41751 GSM1023559 AgeControl rep1
GSE41751 GSM1023560 AgeControl rep2
GSE20538 GSM516173 fibroblast C1-0
GSE20538 GSM516174 fibroblast C1-1
GSE20538 GSM516175 fibroblast C1-10
GSE20538 GSM516176 fibroblast C2-0
GSE20538 GSM516177 fibroblast C2-10
GSE20538 GSM516178 fibroblast C3-0
GSE20538 GSM516179 fibroblast C3-1
GSE20538 GSM516180 fibroblast C3-10
GSE17549 GSM437504 CONT CD14 1
GSE17549 GSM437505 CONT FB 18
GSE17549 GSM437506 CONT CD14 2
GSE17549 GSM437507 CONT CD14 3
GSE17549 GSM437508 CONT CD14 14
GSE15537 GSM389321 CRL-2072(1)
GSE15537 GSM389322 CRL-2072(2)
GSE15537 GSM389323 CRL-2072(3)
GSE16524 GSM415037 Normal Puerto Rican control 1
GSE16524 GSM415038 Normal Puerto Rican control 2
GSE16524 GSM415039 Normal Puerto Rican control 3
GSE16524 GSM415040 Normal Caucasian control 4
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Table 5.9: Identifying edges within BRAS-associated gene networks and KRAS-
associated gene networks using co-expression observed within each subgroup.
Edges reported had a correlation coefficient less than -.7 or greater than .7.
BRAF- BRAF+ KRAS- KRAS+
MAPK3 & CCDC88A ARAF & KIDINS220 IKZF3 & EPB42
RAP2B & RAP2C BRAF & RHEB IKZF3 & HNRPC
KIDINS220 & RAP2A NTF3 & APBB1IP
NTRK3 & RALB
RAF1 & IKZF3
RALA & ARAF
RALA & UBE2K
RALB & NTRK3
RALGDS & CREBBP
RAP1GDS1 & NTRK3
RAP1GDS1 & RALB
RASSF2 & KRAS
RASSF2 & NTRK3
RGL2 & KRAS
RGL2 & NTRK3
RGL2 & RASSF2
UBE2k & ARAF
RASSF2 & APBB1IP
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Figure 5.8: Boxplot of normalized gene expression profiles within only melanoma
cell lines.
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Figure 5.9: Density plots for the posterior probability of the flexmix groups in
(A) SU2C melanoma cell lines and (B) CCLE melanoma cell lines. These plots
reveal that the flexmix called clusters were most distinct in the SU2C melanoma
cell lines.
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Figure 5.10: Circular network graph of all common nodes. Top network rep-
resents the network derived from correlation associations found in cluster one,
whereas the bottom network represents the edges present in cluster two. Density
of the edges highlights the differences in networks.
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Figure 5.11: Pairwise correlation between MAPK Pathway genes from the iden-
tified clusters in TCGA melanoma patients using flexmix were used to generate
heatmaps. Upper right hand half of matrix were correlation coefficients from clus-
ter 1, whereas lower left hand half of matrix were correlation coefficients from clus-
ter 2. Heirarchical clustering was subsequently performed using either distances
from cluster 1 coefficients (left) or cluster 2 coefficients (right).
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Figure 5.12: Pairwise correlation between MAPK Pathway genes from the iden-
tified clusters in all CCLE cell lines using flexmix were used to generate heatmaps.
Upper right hand half of matrix were correlation coefficients from cluster 1, whereas
lower left hand half of matrix were correlation coefficients from cluster 2. Heirar-
chical clustering was subsequently performed using either distances from cluster 1
coefficients (left) or cluster 2 coefficients (right).
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Figure 5.13: QQ-plots for p-values based on association tests for gene copy num-
ber variation observed against the groups discovered in the CCLE dataset, using
either the melanoma subset (top) or against all cell lines (bottom).
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Figure 5.14: Observed p-values based on correlation strength tests. Correla-
tions were compared between those derived from TCGA melanoma patients with
BRAFv600e mutation against those derived from BRAF wt. Blue points repre-
sent edges significant in only BRAF-, red points represent points significant in only
BRAFv600e+, black points represent significance in both.
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Figure 5.15: Density plot of node centrality statistics for flexmix clusters called
on TCGA melanoma patients. We use four different degree centrality parameters
(A) Centrality, (B) Closeness, (C) Betweenness, and (D) Eigenvector Centrality.
133
A. B.
C. D.
Figure 5.16: Density plot of node centrality statistics for flexmix clusters called
across all CCLE cell lines. We use four different degree centrality parameters (A)
Centrality, (B) Closeness, (C) Betweenness, and (D) Eigenvector Centrality.
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Figure 5.17: Comparing node centrality statistics for BRAF+ and BRAF- from
the SU2C cell lines. We use four different degree centrality parameters (A) Cen-
trality, (B) Closeness, (C) Betweenness, and (D) Eigenvector Centrality.
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Figure 5.18: Comparing node centrality statistics for KRAS+ and KRAS- from
the SU2C cell lines. We use four different degree centrality parameters (A) Cen-
trality, (B) Closeness, (C) Betweenness, and (D) Eigenvector Centrality.
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Figure 5.19: Comparing node centrality statistics for BRAFv600e+ and BRAF-
from the TCGA melanoma patients. We use four different degree centrality pa-
rameters (A) Centrality, (B) Closeness, (C) Betweenness, and (D) Eigenvector
Centrality.
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Figure 5.20: Network derived from edges present in TCGA BRAF+ patients.
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Figure 5.21: Network derived from edges present in TCGA BRAFv600e+ pa-
tients.
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Figure 5.22: Network derived from edges present in TCGA BRAF- patients.
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Figure 5.23: WGCNA derived modules (with k = 20) used for a priori assessment
of network rewiring. (A) Beanplots of overlapping modules between melanoma cell
line BRAF+/- (red) and random permutation-based (gray) overlap (B) Beanplots
of overlapping modules between melanoma cell line KRAS+/- (blue) and ran-
dom permutation-based (gray) and (C) Beanplots of overlapping modules between
TCGA melanoma patient BRAF+/- (red) and BRAFv600e+/- (dark red) overlap
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Figure 5.24: Density plots of the observed pairwise correlation coefficients when
comparing the BRAF+/- subgroup using the BRAF-associated gene network and
the KRAS+/- subgroup using the KRAS-associated gene network.
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Figure 5.25: GeneMANIA circular view of all genes in Supplemental Table 2,
i.e., genes with strong interactions identified via co-expression analysis.
Chapter 6
Conclusion, Limitations and
Future Research
6.1 Synopsis
6.1.1 Reproducibility and Reliability of Drug Screen and
Drug Target Data
There have been several attempts to assess the reliability and reproducibil-
ity of high throughput drug screen data (HTS). However, these attempts may not
have accounted for important technical and biological factors (e.g., dose concentra-
tions, efficacy, multiple cancer types, heterogeneity, etc.) or for certain experimen-
tal factors (e.g., plate effects, the laboratory in which assays were performed, etc.).
I assessed the variability in HTS data attributable to both biological and experi-
mental factors in order to ascertain the reliability of such studies. By accounting
for variation attributable to, e.g., the plating scheme, the specific cell lines studied,
the drugs used, and the concentration ranges, I was able to partition the sources
of variation into coherent factors for more compelling inferences in those screens
about the activity of the drugs, or potential targets for drugs.
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6.1.2 Analysis of Dose Response Data
In HTS studies investigating chemotherapeutic agents, there are numerous
analytical issues that need to be considered to reach robust and reliable results.
Through simulation tests, I showed that traditional methods of assessing specific
cell line response to drugs independently of other cell lines can lead to lower sen-
sitivity to detect important factors mitigating drug responsiveness. Additionally,
I found that fitting dose response curves and exploring those curves’ relationships
to other factors (such as mutational status or gene expression values) by lever-
aging all the data available in the drug screen produced greater power to detect
associations. In particular, I demonstrated that using statistical analysis lever-
aging entire dose response curve profiles, rather than single point statistics such
as the traditional IC50 value, was more powerful to detect associations between
drug response and other factors. I also found that incorporating significantly as-
sociated covariates into an analysis directly, rather than in a traditional ad hoc
manner, mitigated many problems with traditional analysis methods. Ultimately,
the methods I described, implemented and evaluated provide more robust methods
for assessing drug responses in HTS data because they directly consider different
sources of variation and confounding effects.
6.1.3 Exploring Evidence for Re-Wiring in Cell-Lines Used
in Drug Screens
In my analyses of melanoma cell lines and TCGA melanoma patient data, I
observed significant heterogeneity that could plague traditional analyses. I found
evidence of heterogeneity by using mixture models to search for clusters or groups
of cell lines and tumors that appeared to exhibit evidence of different relationships
among genes based on correlations in their expression values. These differences
suggest that genetic networks may be “rewired” in subsets of cell lines. The iden-
tification of these network perturbations could impact our understanding of disease
pathogenesis and discovery of drug targets. I did not find evidence for single al-
terations (e.g., mutation status) that could explain the clusters, which further
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suggests that the factors mediating rewiring are complex. Subsequent analyses
with different data sets validated the presence of the overall network differences
and evidence of re-wiring. Based on the differences in genetic networks that I iden-
tified in subgroups of cell lines and tumor profiles I concluded that the genes acted
as central network “hubs” and considered them candidate drug targets. These
analyses suggest that different genes play a more pronounced role in the differ-
ent genetic network architectures that the groups of cell lines exhibited and thus
revealed different drug targets.
6.2 Extensions Beyond Current Experimental De-
signs and Methodologies
There are many issues that my research did not address that potentially
limited my analyses and results. For example, one of the main challenges in cell
line-based HTS and drug screen studies in general is that the dosing schemes
used often do not result in noticeable effects on the cell lines for many drugs. This
could be due to the drugs simply not having an effect or the dosages used not being
appropriate to elicit an effect. If the higher doses considered show partial signs of
an effect in cell lines, then one could expand the dose range, but this would come at
a higher experimental cost. Partial dose response data causes major problems for
the proposed NLME models assessing dose-response relationships. In most cases,
drugs with a lack of response across all samples fail to produce reliable NLME
model fits, as may be expected. Extrapolating the fitted dose response curves to
dosages not considered in the actual screening could be considered, but is highly
problematic because concentrations beyond the range considered in the experiment
are arguably non-translatable to patient treatment due to the potential toxic effect
larger doses would have.
Another important consideration in HTS and drug screening studies in-
volves the use of drug combinations [Winter et al., 2012]. Because cancers often
arise from perturbed networks that implicate many genes or even additional ge-
netic networks, understanding combined drug effects could shed light on the utility
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of “cocktail” chemotherapeutic agents provided to a patient. Applying computa-
tional approaches that consider drug synergy and antagonism could help expose
why certain chemotherapies only work with other drugs. However, testing each
and every pair of drugs or set of drugs that may exhibit an effect would be burden-
some. Thus, computational approaches would need to guide experiments towards
the most likely set of potentially synergistic and antagonistic drug combinations.
Identifying multiple drug targets for drug combination studies could be facilitated
through the proposed network analyses because multiple genes playing more cen-
tral roles in those networks could be identified. Complementary to the drug efficacy
experiments and methods, is the importance of uncovering any potential combined
drug toxicity effects through experimental and computational approaches [Bulusu
et al., 2016]. This could help identify potential drug combinations that would be
too lethal to administer to patients.
Ideally, any identified central network “hubs” that emerge from a network
analysis of the type I pursued would also be experimentally validated. Although
there are many methods for pursuing this, two methods for validating the role
of specific genes contributing to drug response based on re-wiring analysis I con-
sidered involve: (i) obtaining gene expression microarray and RPPA data on cell
lines pre- and post-treatment of drug candidates, treating the cell lines with the
candidate drugs, and then determining if changes in the networks thought to be
rewired occur; and (ii) running clustered regularly interspaced short palindromic
repeats (CRISPR) [Horvath and Barrangou, 2010] [Cong et al., 2013] experiments
to remove or inactivate the central genes revealed from the gene centrality analyses
of the identified rewired networks, in order to create an overall pathway of the type
anticipated from the network centrality analyses.
6.3 Informing Clinical Trials and Patient Data
Analyses
The real motivation for drug screens and the analytical methods I pre-
sented is to encourage the use of the insights obtained in actual clinical trials
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and patient assessments. In this light, the melanoma cell line experiments lever-
aged material that was obtained in the context of the well-known but controversial
Stand-Up-To-Cancer (SU2C) Melanoma Dream Team clinical trial (see Figure 5.1
for a schematic on how they were envisioned for use in the trial). In the clinical
trial, patients were either randomized to a control arm (providing standard-of-
care assignment of chemotherapy) or to an experimental treatment arm (providing
therapies determined by an analysis of patient tumor profiles). The primary end-
point was tumor-free survival at eight weeks. The motivation for providing specific
drugs to a patient, based on the analysis of that patient’s tumor profiles, in the
experimental therapy arm of the trial is to leverage available knowledge linking
specific drugs to features in the patient’s tumor. This knowledge could come from
the results of other trials, knowledge of the basic mechanisms of action of a drug or
drugs, physician intuitions, tumor board deliberations, or the results of empirical
drug screens on the patient’s tumor or a similar patient’s tumor. I intended to
incorporate results from my analyses on connections among drug responses, cell
lines and patient tumors into prediction models that guide therapeutic choices.
Toward this goal, I began developing models based on the cell line gene expression
and RPPA data and applied cross-validation methods to demonstrate the feasibil-
ity of predicting drug responses, at least in a retrospective way given the drugs
ultimately provided to the patients in the trial. However, due to a delay in patient
accrual and subsequent data processing, I have not been able to validate these
models on the data obtained from the outcomes of the patients. Nonetheless, I
believe that our methods provide a robust framework for identifying genes and
networks associated with drug response. These methods provide a path forward
to understand the underlying mechanism in e.g., BRAF mutant and BRAF wild
type patients. Furthermore, it is hoped that by matching patient tumor profiles
to specific cell line profiles for which we have evaluated drug responses using the
methods described herein, patients could be assigned a probability of responding
to each drug based on e.g., receiver operating characteristics (ROC) curves [Han-
ley and McNeil, 1982], and this could provide a broad framework to measure the
effectiveness of our models.
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Figure 6.1: Flowchart of clinical trial study pursued through SU2C. The overar-
ching goal is to incorporate algorithms developed through analysis of in vitro and
other organisms.
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6.4 Closing Remarks
The underlying motivation for the studies and analyses I pursued was to
identify and provide solutions for problems that have received a great deal of at-
tention in literature concerning the use of cell-line based drug targeting, HTS and
general drug screening strategies. I have shown that there is a need for great
sensitivity to factors likely to impact the reproducibility and reliability of drug
screen and drug target data. I have also shown that existing ways of analyzing
dose-response curves derived from drug screen data are flawed and could be com-
plemented by more sophisticated analytical methods. Finally, I have shown that
many cell lines and tumor profiles considered in drug target identification and
screening analyses may exhibit differences in the genetic networks that could im-
pact the identification of logical drug targets or inferences about molecular disease
pathogenesis. In light of these results, I consider my efforts as opening up new
avenues of research and hope to see the community improve upon them.
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